Analysis of anti-proliferation activities of drought tolerant soybean lines. by Yuen, Ka Leung. & Chinese University of Hong Kong Graduate School. Division of Life Sciences.
Analysis of Anti-Proliferation Activities of Drought Tolerant Soybean Lines 
YUEN, Ka Leung 
A Thesis Submitted in Partial Fulfillment 
of the Requirements for the Degree of 
Master of Philosophy 
in 
Biology 
The Chinese University of Hong Kong 
September 2009 
學大 
w / 统 系 份 書 圓 
— — — 
1 5 FEB 2011 
V . , 'INiVERSiTY 
Thesis committee: 
Prof. FUNG, Ming Chiu (Supervisor) 
Prof. WONG, Yum Shing (Chairman) 
Prof. LAM, Hon Ming (Committee member) 
Prof. MAK, Nai Ki (External examiner) 
Statement 
All the experimental work reported in this thesis was performed by the author, 
unless otherwise specified. 
YUEN, Ka Leung 
Acknowledgement 
I owe my deepest gratitude to thank the ones who help to make this thesis 
possible. 
I would like to express my gratitude to my supervisor. Prof. Ming Chiu, FUNG 
for his guidance, understanding and support from the beginning to the end. Studying 
under his supervision not only enriched my knowledge, but also helped me to reveal 
the meaning of scientific research. 
I would like to thank my committee members, Prof. H.M. LAM and Prof. Y.S. 
WONG for reviewing my thesis and providing valuable comments. 
I would also like to offer my regards to all the labmates, who supported and 
shared meaningful discussion with me during the completion of the project. I would 
like to thank Ms. Josephine, S.M. Liu, Mr. S 
Mr. S.W. Zhang, Mr. X.W. Chan, Mr. K.M 
giving support and advice in any respects. 
Hu, Mr. Hogan, 
Wong, Mr. K.H. 
H丄.Tang, Mr. Kan Liu, 
Mak, Mr. W.K. Lau for 
III 
Abstract 
Cancer is a disease affecting people all around the world. It is estimated that the 
populations being affected by cancer will keep increasing in the near future. While the 
current cancer therapies are not satisfactory, isoflavones found in soybean are reported 
as one of the possible anti-cancer drug candidates. 
As a secondary metabolite synthesized in soybean, the production of isoflavones 
can be influenced by many factors including external environment and internal 
genomic variations. While an intergraded study concerning the isoflavone contents 
from various soybean lines and at the same time the corresponding anti-proliferation 
abilities has not been performed, the project analyzed the isoflavone contents of 10 
drought tolerant soybean lines by HPLC and their anti-proliferation activities on 5 
human cancer cell lines. 
The results indicated a significant variation in isoflavone contents and the 
potency of anti-proliferation on cancer cells in various soybean lines. The parent 
soybean D19 (U) was found to produce more of the 5 selected isoflavones than its 
offspring. However the offspring are more potent in anti-proliferation activities. 
Statistical analysis has revealed the influence of genotype and isoflavone production 
and anti-proliferation abilities. Irrigation was also found to stimulate the production of 
the 5 selected isoflavones, while its effect on the anti-proliferation activities is 
inconclusive. The anti-proliferation effect of soybeans on MCF7 cell line (breast 
cancer) was found to be correlated with the amount of daidzin and genistin in the soy 
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1.1.1. Overview of cancer 
Cancer is a group of disease due to uncontrolled cell growth. The disease 
basically occurs in the higher multi-cellular organisms with renewable tissues (1-3). 
In medical science, cancer is defined more precisely as an abnormal growth of cells 
caused by multiple changes in gene expression, which leads to the dysregulated 
balance of cell proliferation and cell death, and ultimately evolving into a population 
of cells that can invade tissues and metastasize to distant sites, causing significant 
morbidity and, if untreated, death of the host (1). 
1.1.2. Development of cancer 
The multistep carcinogenesis model was firstly proposed in 1980s, and it is now 
commonly accepted that the development of cancer is a stepwise process. Although it 
is a continuous process, in the model, carcinogenesis is generally divided into 
initiation, promotion and progression (1, 4-12). 
Initiation In initiation, the normal cells are exposed to various carcinogens. 
Various kinds of carcinogens interact with the macramolecules like DNA and proteins 
in the cells in different ways. Those interactions eventually cause DNA sequence 
alternations, which can usually be restored by the DNA repairing mechanisms in the 
cells. However, the occasional malfunctioning of the repairing system will allow the 
fixing of sequence alternations into genome, resulting in irreversible mutations. When 
these mutations accumulate in proto-oncogenes or tumor suppression genes, the cells 
will eventually escape from the controlling system and acquire the ability of unlimited 
proliferation (7). 
Promotion From the initiation stage, the cells have possessed the ability for 
uncontrolled proliferation. In promotion stage, the DNA sequence is altered and 
mutations accumulated in the genome. With various types of mutations, some of the 
cells can proliferate at a faster rate than the others. These cells are naturally selected 
and gradually expanded into a visible polyps or tumor (8-10). The growth is described 
as benign tumor at this stage. 
Progression The progression stage refers to the development of benign tumor 
to malignant neoplasm. Cells in this stage are characterized by their high proliferation 
rate and also genomic instability. Irreversible mutations continue to accumulate in the 
genome, finally leading to the acquisition of invasive ability in benign tumor cells. 
The cells can invade the surrounding tissues including the blood vessels and lymph 
system. They invade into these circulating systems and metastases throughout the 
body. The situation is described as cancer (9-12). 
A well studied example for this stepwise development of malignancies through 
accumulation of gene mutations is colon cancer. In initiation, the long term exposure 
to carcinogens will probably cause DNA alternations in colon cells. At the promotion 
stage, the two mutated APC alleles in colon cells will lead to uncontrolled 
proliferation leading to the formation of adenomatous polyp. Further mutation in RAS 
gene will give rise to the development of dysplastic polyp. Due to the genomic 
instability of tumor cells, tp53 will also be mutated as the cells proliferate and finally 
lead to the formation of tumor. In progression stage, further chromosomal aberrations 
will lastly result in metastatic carcinoma (13-15). 
1.1.3. Characteristics of cancer cells 
Despite originates from the normal cell, cancer cells have several characteristics 
discriminating from the non-cancerous tissues. These include the self-sufficiency in 
growth signals, insensitivity to growth-inhibitory signals, evasion of programmed cell 
death, sustained angiogenesis, limitless replicative potential, tissue invasion and 
metastasis (16), and dedifferentiation of cells (1). The last three are selected for the 
following discussion. 
Limitless replicative potential Unlimited proliferation is an important 
character of cancer cells. Recent researches have pointed out that although 
self-sufficiency in growth signals, insensitivity to growth-inhibitory signals and 
evasion of programmed cell death are involved, these three features alone are not 
enough for the expansion of tumor growth (16) and additional mechanism is required. 
Upregulated expression of telomerase is proposed as one of the possibilities. In nature, 
about 100 base pair of DNA at the 3' end will be lost in each round of DNA 
replication. It is due to the inability of DNA polymerase to completely replicate this 
telomere region. After rounds of replication, the telomere will be so short that can no 
longer protect the 3’ end of DNA. The unprotected DNA may undergo mutations, 
resulting in chromosomal rearrangements and eventually cell death (16). As the 
function of the telomerase is to maintain the length of telomere, it is therefore 
suspected that the prevalent upregulated expression of telomerase in cancer cells is 
related to the limitless proliferation potential as it can prevent the cancer cells dying 
from shortening of telomere (16-19). 
Tissue invasion and metastasis Metastasis is another important character of 
cancer. It refers to ability of cancer cells to escape from its originated site, spreading 
through and establishing secondary malignancies in the body (16，20-21). Metastasis 
usually occurs in the late stage of cancer development (16). For the cancer cells, 
metastasis allows the continuous development of primary tumor without limited by 
the space and nutrients (16), while for the patient metastasis can disrupt the function 
of vital organs. This phenomenon accounts for more than 90% of cancer deaths (16， 
21-23). The cancer cells undergoing metastasis will adjust their expression profile of 
cell-cell adhesion proteins from a highly adhesive isoform to the poorly adhesive form. 
The expression of the extracellular proteases will also be upregulated (16，23). These 
modifications facilitate the release of cancer cells into circulating systems for 
metastasis. 
Dedifferentiation of cancer cells In general, cancer cells are structurally and 
functionally less well differentiated when compared with their normal counterparts in 
the they tissue raised (1). For example, the breast carcinomas trend to develop into 
some mammary gland structures and, the islet cells in pancreas cancer retain the 
ability to produce insulin. These features are considered to be immature as they can 
only be observed in the progenitor but not in the normal mature cells (1). As the 
cancer cells retain these immature properties, they are considered as dedifferentiated 
when comparing with the normal mature counterparts. 
Morphological features Cancer cells are morphologically different from 
their normal counterparts when examined under microscope. In general, the cancer 
cells are more variable in size and shape (1). They have large and irregular nucleus, in 
which nucleoli can often be observed (24). As the cancer cells are actively dividing， 
the proportion of cells undergoing mitosis in a cancer cell population is much higher 
than that in normal cell population (1). In addition, owing to abnormal mitosis, giant 
cells with much larger size and multiple nuclei can often be observed in cancer tissues， 
but seldom in normal ones. 
1.1.4. Categorization of cancer 
Cancer can arise from any cells capable of proliferation. When the disease 
originates from different tissues, it varies in pathologies such as the metastasis sites. 
Categorization of cancer is therefore important as it can assist to forecast the 
progression of the disease and help in the choice of therapy (1). 
The system currently adopted by the field basically categorizes the cancer into 
three groups, namely carcinoma, sarcoma and leukemia. 
Carcinoma Carcinoma is the most common type of human cancer which 
arises from the epithelial cells. According to the histology, carcinoma can be further 
classified into different subgroups. For example the squamous cell carcinoma arises 
from squamous epithelium or adenocarcinoma from glandular epithelium (25-26). 
Sarcoma Sarcoma refers to the cancers in connective tissues. The disease 
starts from the mesenchymal tissues, including the bone，muscle and nerve fibre. The 
disease is relatively rare in human (25-26). 
Leukemia Cancers originated from the hematopoietic system are classified 
as leukemia. Leukemia can be subdivided into an acute form or the chronic form 
according to the pathology, and into lymphocytic and myelogenous by type of blood 
cells being affected (1). Leukemia mainly affects the children, and it has no benign 
counterparts. Once the cells acquire the ability to divide in an uncontrolled manner, 
they can spread through the body by the circulation systems (1, 25-26). 
1.1.5. Risk factors in cancer development 
Although carcinogenesis is due to the mutations in genes, the cause of mutations 
has not been fully developed. For years, scientists have identified a lot of risk factors 
(e.g. chemical exposure) which can lead to mutations in DNA. 
Chemicals exposure Exposure to chemicals has known to be the cause of 
carcinogenesis for many years (27-29). Recent researches indicate that the mutagenic 
effect of chemical carcinogens is mainly due to the covalent bond formed between the 
electrophilic compound and the nucleophilic site on macromolecules including 
proteins and DNA (28). Most of the chemical carcinogens are actually not mutagenic 
before metabolic activation. However, when they circulate in the body, these 
chemicals will be processed by metabolic pathways and being converted to the 
electrophilic form (29-34). The electriphilic chemicals react with the DNA, causing 
mutations and contributing to the development of cancer. 
The possible link between long term exposure to chemicals and occurrence of 
cancer had been proposed since the sixteenth century. In 1567, Paracelsus firstly 
proposed the cause and effect relationship between exposure to some unknown 
compounds in mine ores and the incident of "wasting disease of miners", which is 
known as lung cancer much later. Reports supporting the speculation accumulated 
since then. In 1761，the English physician John Hill reported that the appearance of 
nasal cancer may be related to the continue exposure to the snuff. Later, another 
English physician Percival Pott also noticed that the high incidence of scrotal cancer 
in chimney sweepers may be related to the repetitive local contaminations by soot. 
The surgeon Rehn also recorded the possible association on the high frequency of 
urinary bladder cancer in German dyestuff industry workers and the production of the 
aniline dye in 1895 (1,28, 34). 
By the end of century, it was generally accepted that long term exposure to 
certain chemicals would cause cancer. However, the hypothesis was not confirmed 
until 1915，when the Japanese scientists Yamagiwa and Ichikawa successfully induced 
skin cancer on the rabbits by applying coal tar on their ears continually (27-28, 34). 
Many other chemical carcinogens had been identified since the success of 
Yamagiwa and Ichikawa. One of them is polycyclic aromatic hydrocarbon. Polycyclic 
aromatic hydrocarbon (PAH) is a group of compound that can be found in coal tar and 
cigarette smoke. It is generally believed that the metabolic conversion of PAH to 
dihydrodiol epoxides leads to its carcinogenic activities. For instance, it is found that 
benzo(a)pyrene, one of the polycyclic aromatic hydrocarbons, is converted to 
7p,8a-dihydroxy-9a, 1 Oaepoxy-7,8,9,10-tetrahydrobenzo(a)pyrene, the actual 
mutagenic metabolite of benzo(a)pyrene that can cause skin, lung and stomach cancer 
(27，32，34). 
Irradiation The speculation of radiation would cause certain kind of damage 
to the human body had been proposed shortly since its discovery (35). Many reports 
in the later time had indicated the link between irradiation and carcinogenesis (35-37). 
In addition, the children were found to be more vulnerable to radiation and developed 
cancer (38-40). According to the differences in nature, radiation can be further 
classified into ionizing radiation or ultraviolet radiation. 
Ionizing radiation refers to the radiation capable of producing ionization when 
passing through a substance (1). The examples include the X-ray, gamma-ray, protons 
and alpha-particles (1). The mutagenic effects of these radiations are due to their 
abilities of generating free radicals. These free radicals can cause single or 
double-strand breakage in DNA, point mutations and even chromosomal translocation 
(1,35,41). 
Ultraviolet radiation induces different types of damage to the DNA molecules 
depending on the wavelength concerned. Ultraviolet-A，with a wavelength of 320-400 
nm, can produce oxidative lesion via photosensitization mechanism (1，42-43). With 
shorter wavelength and higher energy, ultraviolet-B can cause the formation of 
cyclobutane pyrimidine dimmers such as thymine-thymine dimmers (1’ 43-44). Base 
transition from C to T will be resulted if the damages are not repaired before DNA 
synthesis, and this result in mutations. 
Case studies on radiation related accidents also evident the carcinogenic effect of 
radiation. In 1986, a nuclear reactor in Chernobyl exploded, released a huge amount 
of radioactive isotopes into the surrounding environment. People living around the 
region were found to have a high incidence of thyroid cancer by many studies of the 
accident (45). 
Another piece of evidence comes from the investigations on survivors of atomic 
bomb explosion in Japan during World War II. It was found that, many survivors 
developed various kinds of cancers including oral cavity, esophagus, stomach, colon, 
liver, lung, skin, breast, ovary, bladder, nervous system and thyroid in the later stage 
of their lives (46). Radiation not only affected the survivors, but also their offspring. 
They were bom with different kinds of defects (46). 
Others Other risk factors include aging (47-48)，infection by virus (49-51) and 
living style (52-53). They are also considered as important risk factors for 
carcinogenesis while they are not discussed in details in here. 
1.1.6. Epidemiology of cancer 
Cancer is a global problem affecting the whole human species. Reports from 
WHO indicated that cancer was the worldwide leading cause of death in 2004 (54). 
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In that single year, the disease had accounted for around 13% of total death in the 
world thus 7.4 million lives. The number of cancerous deaths is estimated to rise to 12 
million by 2030 (54). Such an increase can be explained by many reasons, and one of 
them is aging. Thanks to the advancements in new diagnostic and therapeutic 
technologies, many diseases are now curable. In the past few decades, deaths due to 
the infectious diseases or cardiovascular diseases have dropped significantly (1，55). 
The human life span has extended to the age with a high risk of developing cancer by 
allowing enough time for the accumulation of mutations (55-58). 
Despite as a global disease, the epidemiology of cancer varies around the world. 
Variations in the incidence of particular cancer and corresponding mortality can be 
observed among different races, and between developed and developing countries (54， 
57-58). Such divergences are reasoned to the accessibility to medical facilities, 
contrasting living styles and genetics backgrounds between the populations (54, 
57-58). 
Cancer epidemiology in developed countries In the classic developed 
country, the United State, it is estimated that 1 in every 3 man will develop some 
kinds of cancer in his life time, and eventually 1 in every 5 American will die of 
cancer (57-58). Recent data also suggested that the number of deaths due to cancer 
had been over 500,000 in 2008, and more than 1.4 million new cases had been 
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diagnosed in the same year (59). The most prevalent cancer is the prostate cancer in 
man and breast cancer in woman. These cancers account for about 25% of new cases 
in each sex. The second most common cancer is the lung and bronchus cancer with 
215,020 new cases identified. Colon and rectum cancer is the third most common 
cancer, contributing to about 10% of total new cases in 2008 in America (59). 
Among the prevailing cancers, lung cancer has the highest mortality rate. In the 
United States, the disease killed more than 160,000 people in 2008, accounting for 
more than 28% of total cancer deaths. Regardless of their prevalence in the two sexes, 
prostate cancer and breast cancer are less fetal. They have the second highest 
mortality rate counting for 10% and 15% cancer deaths, respectively. The colon and 
rectum cancer is even less fetal, accounting for about 9% of cancer deaths and ranked 
to be the third killing cancer (59). 
Cancer epidemiology in developing countries The cancer epidemiology 
in developing country (e.g. China) is different from America. It was estimated that 
more than 2.4 million new cases had been diagnosed in 2005 in China. Cancer is the 
3rd cause of death in that year, taking away more than 1.8 million lives. The most 
common malignancies in Chinese male and female are the same. They are the 
stomach cancer, lung cancer and liver cancer (54, 60). The number of new cases in 
near future is expected to keep increasing due to the adoption of Western live style, 
12 
with respect to high intake of calories, lack of physical activities and obesity in China 
(60). 
1.1.7. Cancer therapies 
Cancer can now be cured if it is diagnosed at early stages. The therapy is 
regarded to be succeeded if the patient survives for five years with no recurrent of 
malignant tumors. This five years survival rate depends on the degree of malignancy 
at the time of diagnosis. There are mainly 3 ways to treat cancers, and the choice of 
therapies is determined by the tissue of origin, position of tumors and level of 
malignancy (1). 
Surgery In theory, cancer can be cured by completely removal of cancerous 
cells. Therefore it is no doubt that physical removal of malignant tumors by surgery is 
one way of treatments (61-63). The strategy is usually adopted when cancer is 
diagnosed at early stage and has not widely metastasized in the body. 
Surgical removal of cancer seems to be simple and effective, but the method has 
a few limitations. Although the disease can be cured by complete removal of cancer 
cells, this target may not be easy to achieve due microscopic metastasis. Microscopic 
metastasis refers to spread of cancer cells in microscopic level. A few cancer cells 
may have invaded into the surrounding normal tissues, which can hardly be detected 
and therefore not removed. Consequently, even though the major part of the tumor is 
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extracted, the remaining few cancer cells can re-grow into a new malignant tumor 
(64-66). 
Another limitation of surgery is that the location of the primary tumor must be 
identified and at an operable position. Sometimes the patient goes for the medical 
checkup because of certain cancerous symptoms. However, a particular symptom can 
often be shared by different kinds of cancer, or even caused by the secondary tumors 
at common metastasis sites like the lung and the spine. These make the tracking of 
primary tumor difficult. Without identifying the primary tumor, cancerous tissue 
cannot be completely removed by operation. In addition, the tumor must not be 
located too deep inside the body or near some vital organs. Otherwise, surgery will 
not be feasible (1). 
As mentioned the above, surgery will only be suitable for cancer at early stage. 
At the later stages of development, the malignant tumor cells will metastasize to 
different parts of the body. The physical condition of the patient may not be good 
enough to withstand multiple surgeries. Furthermore, the chance for microscopic 
metastasis will be much higher at the late stages, which will lead to the failure of 
treatment (1). 
Chemotherapy When the tumor is identified to be surgically unresectable, 
chemotherapy is the alternative. Chemotherapy refers to selectively kill the cancer 
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cells with the use of chemicals. Research on chemotherapy started about 60 years ago. 
Now, more than 100 anti-cancer drugs have been approved by the American Food and 
Drug Administration and are now put in clinical use (67-68). 
The anti-cancer drugs currently in use basically target the genetic abnormalities 
that give rise to the abnormal production of specific molecules in cancer cells (68). 
The drugs can be classified into different groups according to their mechanisms. They 
include the DNA fragmenting agents, protein synthesis inhibitors, topoisomerase I/II 
poisons, purine analogues, antimetabolites, alkylating agents, fluoropyrimidines, 
anthracyclines, antimicrotubules agents and newly developed platinum-based 
compounds (69-71). Though with different working mechanisms, all these anti-cancer 
drugs kill the cancer cells through apoptosis (69-71). 
After being studied for decades, chemotherapy still has some unsolved 
restrictions. Theoretically, the anti-cancer drugs can target and selectively kill the 
cancer cells by recognizing the unique characteristics expressed by the cancer cells (1， 
68). However, in the real situation, the designated characteristics can often be found 
on the normal cells. An example is the use of purine analogues. Cancer cells generally 
proliferate, and therefore synthesizing DNA, at a speed much faster than the normal 
cells. By making use of this characteristic, a large amount of purine analogues will be 
incorporated into the newly synthesized DNA in cancer cells and exert the cytotoxic 
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effect. Besides the cancer cells, some other normal cells in the body are also dividing 
actively, such as the hair follicle cells and the intestine epithelium cells. With the 
sample principle, the purine analogues can also kill these normal cells and cause 
undesirable side effects on the patients. The specificity of the killing effect has always 
been the largest constraint of the anti-cancer drugs and limiting their use (72-74). 
Chemotherapy works by inducing the cancer cells to undergo apoptosis, thus 
relying on the intrinsic biochemical pathways to eradicate the targeted cells. However, 
due to the instability of the genome in cancer cells, the genes involved in designated 
biochemical pathway may be mutated during the therapy, leading to the drug 
resistance (75-77). An example is the expression of fibroblast growth factor 2 (FGF-2) 
in small cell lung cancer (SCLC) after etoposide treatment (78). The expression of 
FGF-2 in cancer cells can inhibit the Smac protein, which helps to remove the 
inhibitor of apoptotic protein (lAP). In addition, FGF-2 also increases the translation 
of genes coding for anti-apoptotic protein including BCLXL, XIAP and IAP-1 (79). 
Through the expression of FGF-2, the SCLC cells will not undergo apoptosis upon 
exposure to etoposide. 
Radiotherapy Radiotherapy is the alternative in cancer treatment. It 
refers to the use of radiation energy to kill the cancer cells. In the therapy, radiation 
will be delivered into the body of patient at a specific dosage and specific site, 
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inducing permanent damage to the DNA or causing damage through production of 
free radicals (80). 
According to the methods of delivering radiation, radiotherapy can be classified 
into brachytherapy, radiopharmaceutical and teletherapy. Brachytherapy involves 
placing short or slow radiation into or near the tumor. Radiopharmaceutical is the 
ingestion of liquid radioactive source (80). A well-known example is the therapy for 
thyroid cancer with ingestion of radioactive iodine-131. With the specific 
characteristic of thyroid grand, the radioactive iodine-131 is taken up and 
concentrated at the thyroid. Radiation can be delivered to the thyroid cancer cells 
directly (81). 
Another type of radiotherapy, radioimmunotherapy, is a combination of 
immunotherapy and radiotherapy. Radioactive antibody will be injected into the 
patient's body. With the help of antibody, the radiation will be delivered to the tumor 
cells more precisely. Although the idea has been demonstrated successfully in the 
treatment of hematopoietic malignancies, a lot more investigations will still be needed 
to overcome the general resistance of solid tumors to the radiation (82-84). 
Another concern of radiotherapy is the developing secondary cancer after the 
treatment. It has been reported that the chance of developing secondary cancer, for 
example soft tissue sarcoma, will increase significantly after radiotherapy for breast 
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cancer or prostate cancer. The concern will definitely limit the use of radiotherapy 
until solutions can be found (85-87). 
From the above, it can be seen that cancer is actually a global burden with no 
satisfactory solutions due to the limitations in the current therapies. Therefore 
identification of an effective anti-cancer drug with no or little side effects has always 
been the goal of the cancer researchers. Isoflavone, the secondary metabolite naturally 
found in the soybean, is one of the candidates. 
1.2. Soybeans and isoflavones 
1.2.1. General introduction of isoflavones 
Isoflavone is a large group of secondary metabolite can mainly be found in the 
family Leguminosae in plant kingdom (88). Although they can also be found in other 
plants, the most common, well-known and well-studied food source of isoflavones is 
the soybean {Glycine max). As a rich source of isoflavones, many different kinds of 
isoflavone including the daidzin, genistin, and glycitin, their corresponding aglycones 
daidzein, genistein, and glycitein can be detected in the soy (88-89). 
1.2.2. Natural functions of isoflavones 
Isoflavones are naturally synthesized by the plants as a secondary metabolite for 
various functions (90-91). It is well known that the isoflavones are involved in the 
progress of nodulation in soybeans. Specific types of isoflavone produced by the plant 
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will stimulate the transcription of bacterial genes including nod, ml and noe, for the 
protein products required for nodulation (90-91). Besides, researches have also 
revealed that the isoflavones are involved in the plant defense system (92-93). 
Isoflavones can be produced as phytoalexin to resist the pathogenic fungi and 
microbes, or even as insect deterrents to prevent the settlement of insect larvae 
(92-93). 
1.2.3. Structures of isoflavones 
The general structure of isoflavone is indicated as below, and different kinds of 
isoflavone vary at the R positions (88). Members in the large isoflavone family differ 
not only on the number and position of the substitutes, but also the oxidation levels 
and even the heterocyclic rings (88). 
R3 0 
genistein, R； - OH; R2 = H; R3 = OH; R, = OH 
genistin, R^  = 0-glucosyl; Rg = H; R3 = OH; R^ = OH 
daidzein, R, - OH; R � - H ; R3 = H; R^ = OH 
daidzin, Rj = O-glucosyl; Rg = H; R3 = H; R^ = OH 
glycitein, Rj = OH; 二 OCHg； R3 = H; R, = OH 
glycitein 7-/ff-0-glucoside, R! = 0-glucosyl; R] - OCH3 
R3 = H; R, = OH 
Fig. 1.2.3 Structure of known soybean isoflavones (88) 
1.2.4. Bioactivities of soy isoflavones 
Anticancer activities The bioactivities of soy isoflavones on human have 
been widely studied for many years. Many studies have pointed out that long-term 
consumption of isoflavone containing soy or soy products is correlated with the low 
incidence of both hormone-dependent and hormone-independent cancers including 
breast cancer, prostate cancer, ovarian cancer, colorectal cancer and lung cancer 
(94-101). Epidemiological studies comparing the incidences of cancer and the Eastern 
and Western diet also correlate the relatively low incidences of cancer in Eastern 
population to the high consumption of soy in Eastern culture (102-103). The 
consistence in the mentioned studies has indicated the significant cancer preventive 
effects of isoflavone. 
Apart from the preventive effects, isoflavones have also been shown to have 
anti-proliferation abilities on cancer cells. As the major isoflavones in soybean, 
genistein and daidzein have been shown to process significant anti-proliferation effect 
on various cancers (104-106). The experiments have been confirmed in the in vivo 
mouse model, and similar results were obtained proving the anti-cancer activities of 
the isoflavones (104-105). 
Anti-osteoporosis activities Besides the anti-cancer effect genistin and 
daidzin are also famous for their nutraceutical effects on osteoporosis, thus lost of 
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bone. The disease is prevalent in postmenopausal females due to the declined estrogen 
level. Studies on mouse bone cell line MC3T3 have proven the stimulatory effect of 
isoflavones on the differentiation of immature MC3T3 cells to the mature bone 
forming cells, osteoblasts (107-108). The growth of the bone removing cells, the 
osteoclasts, can also be inhibited the by isoflavones (109-110). In vivo experiments 
with ovariectomized rat model, which mimic the physiological condition of reduced 
estrogen level, also produced the similar results (111). These studies evidenced the 
effects of isoflavone to relief osteoporosis by adjusting the imbalance of the bone 
making and bone removing cells. 
1.2.5. Production of soy isoflavones can be affected by many factors 
As the secondary metabolite of the soybean, the production of isoflavones can be 
affected by the surrounding environment. It has been reported that the external 
environmental factors including temperature during seed development, carbon dioxide 
concentration (112-114) and altitude and latitude (113) can affect the production of 
soy isoflavones. Besides, the heritable factors thus the genetic makeup of the 
soybeans also play a role (116，117). Certain lines of soybean may produce more 
isoflavones than the others even they are grown under the same environment. 
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Table 1.2.5.1 Summary of effects of studies factors on isoflavonc production 
Studied factors 
Genetic factors Temperature CO2 Concentration Irrigation 
Effect on Affect Increase in Slightly increase Increase the 
isoflavone production temperature, the isoflavones isoflavone 
production (113, 117，118) decrease in production (112) production 
production (115-116) 
(112，114) 
1.3. The aim and objectives of the project 
1.3.1. Aim of the project 
The anti-cancer effects and the environmental influence on production of soy 
isoflavones have been studied independently for many years. However, integrated 
researches concerning the isoflavone contents and anti-cancer activities of various 
genotypically different soybeans have not been carried out so far. Therefore, in this 
project, irrigation was selected as an environmental factor on the bioactivities and 
isoflavone production in various drought tolerant soybeans. 5 isoflavones daidzin, 
glycitin, genistin, daidzein and genistein were selected for analysis in the project. 
They are selected as they represent the major isoflavones found in the soybean 
(88-89)，and they have been reported for various bioactivities (94-111). The project 
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can provide some insights on the effect of genotype and irrigation on the production 
of isoflavones and bioactivities of these special soybeans. 
In the China territory, nearly half of the land has an annual precipitation less that 
400 mm (119). Therefore the project can also help to determine a soybean which can 
be grown in the drought land, and at the same time with a high level production of 
isoflavones. This is important for the full utilization of land resource, helping farmers 
to choose a soybean line which can be cultivated in drought land and at the same time 
with high economic values. It also helps to provide information for selecting the 
suitable soybean line for production of soy-related nutraceutical products (120), 
ensuring the stable and consisting nutraceutical effects of soy products. 
1.3.2. The objectives of the project 
The specific objectives of the project are: 
1. To determine the contents of selected isoflavones in the 19 drought tolerant 
soybean samples by high performance liquid chromatography (HPLC). 
2. To determine the anti-proliferation activities of the 19 drought tolerant soybean 
samples by anti-proliferation assays. 
3. To determine the effect of genotype and irrigation on the anti-proliferation 
activities and isoflavones production of the 19 drought tolerant soybean samples. 
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2. Materials 
2.1 19 drought tolerant soybean samples 
The 19 soybean samples were kindly provided in single blinded manner by Prof. 
H.M. LAM, the Chinese University of Hong Kong. They consisted of 1 parent 
soybean with 9 recombinant inbred lines. 
The 9 recombinant inbred lines were resulted from the genetic cross between a 
salt and drought tolerant soybean, and a salt and drought sensitive soybean. The 
soybeans were the F9 generations and collected from Dunhuang in the summer of 
2008. 
The soybeans were divided into 2 groups and cultivated in different conditions, 
the irrigated land and non-irrigated land. In irrigated land, water was introduced and 
Hooded the land once per 15 days during the whole plantation period. In non-irrigated 
land, the land was only irrigated once before sowing and not irrigated afterwards. 
Soybeans harvested from both lands were provided for analysis. 
The information of the soybeans was disclosed for data interpretation at the end 
of experiment and was tabulated as below. DOl to D18 are the derivatives, and D19 is 
the parent soybean. 






































D18 Irrigated land 
D19 U Irrigated land 
2.2 5 Human cancer cell lines 
Five human cancer cell lines were used as cell models for study of 
anti-proliferation effect of soybean extracts. The cancer cell lines used included the 
human lung adenocarcinoma cell line A549 (121), human chronic myelogenous 
leukemia cell line K-562 (122), human prostatic adenocarcinoma PC-3 (123), the 
human mammary gland adenocarcinoma MCF7 (124) and the human osteosarcoma 
MG-63 (124). 
All the cell lines were obtained from the cryopreservation stock in Prof. M.C. 
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FUNG'S laboratory, the Chinese University of Hong Kong. The A549, K-562 and 
PC-3 (123) cell line was cultured in completed RPMI 1640 medium (See Materials 
2.5). The MCF7 and MG-63 cell line was cultured in completed Minimum Essential 
Medium (MEM) and Dulbecco's Modified Eagle Medium (DMEM), respectively 
(See Materials 2.5). All the cultures were incubated in 37°C incubator with 5% CO2 
and 95% humidity. 
2.3 Chemicals 
1. Acetonitrile (ACN) Lab-Scan 
2. Daidzein Sigma-Aldrich D7802 
3. Daidzin Sigma-Aldrich 30408 
4. Dimethyl sulfoxide (DMSO) Sigma-Aldrich 472301 
5. Ethanol, absolute Scharlau 
6. 2-phenylchromone Sigma-Aldrich F2003 
7. Genistein Sigma-Aldrich G6776 
8. Genistin Sigma-Aldrich G0897 
9. Glycitin Sigma-Aldrich G1296 
10. Methanol Scharlau 
11. Thiazolyl Blue Tetrazolium Bromide (MTT) Sigma M5655 
12. Trifluoroacetic acid (TFA) Sigma T6508 
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2.4 Reagents 
1. Antibiotic-antimycotic (PSF) Gibco 15240-062 
2. Dulbecco's phosphate-buffered saline (DPBS) Gibco 21600-010 
3. Dulbecco's Modified Eagle Medium (Powder) Gibco 12800-017 
4. Fetal calf serum (FCS) HyClone CH330160-02 
5. Minimum Essential Medium (Powder) Gibco 41500-034 
6. Trypsin-EDTA GibcoBRL 25200-056 
7. RPMI 1640 (Powder) GibcoBRL 23400-021 
2.5 Solutions 
DPBS The DPBS powder was dissolved completely in 1 
liter of Milli-Q water and then sterilized by 
autoclave. 
2. Complete Dulbecco's 
Modified Eagle Medium 
(DMEM) 
The DMEM powder was dissolved in Milli-Q water, 
added with sodium bicarbonate to 2 g per liter, 
adjusted to pH 7.2 and filter sterilized by passing 
through a 0.22 \im membrane. The complete 
medium was prepared by supplementing plain 
DMEM medium with 1 % PSF and 10% FCS. 




added with sodium bicarbonate to 2 g per liter, 
adjusted to pH 7.2 and filter sterilized by passing 
through a 0.22 |xm membrane. The complete 
medium was prepared by supplementing plain 
MEM medium with 1 % PSF and 10% FCS. 
Complete RPMI1640 
medium 
The RPMI powder was dissolved in Milli-Q water, 
added with sodium bicarbonate to 2 g per liter. 
adjusted to pH 7.2 and filter sterilized by passing 
through a 0.22 \im membrane. The complete 
medium was prepared by supplementing plain 
RPMI medium with 1 % PSF and 10% FCS. 
5. 5 mg/ml MTT solution 0.5 g MTT was completely dissolved in 500 ml 
Milli-Q water, and then filter-sterilized by passing 
through a 0.22 }xm membrane. 
6. 70% ethanol 560 ml absolute ethanol was fully mixed with 140 
ml Milli-Q water. 
7. 0.2% TFA 2 ml TFA was mixed with 1 liter of Milli-Q water. 
2.6 Major Equipments And Materials 
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2. Microplate reader Molecular Devices Spectra 
3. Sonicator, bath Branson 3210 
4. HPLC system Hewlett-Packard Series 1100 
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3. Methodology 
3.1. Preparation of soybean extracts 
The isoflavone contents of 19 soybean samples were extracted by ethanol. The 
extraction protocol was an integration of methods previously described by Rostagno, 
M. A. (125-126), Achouri, A. (127) and Genovese, M. I. (128) In brief, 2 grams of 
soybean from each sample were ground into powder with diameter < 2 millimeter. 
The powder was immersed in 20 ml 70% ethanol, with addition of 160 |xg 
2-phenylchromone as internal control for calibration of extraction efficiencies. The 
content was incubated at room temperature overnight, and then sonicated for 1 hour. 
The content was then centrifuged at 3500 g for 15 minutes at 4°C, and the aqueous 
supernatant was collected then filtered with 0.22 \im filter (Millipore). The above 
steps were repeated with the residue except the addition of 2-phenylchromone. The 
two batches of filtrate were mixed and dried completely at 45 °C under reduced 
pressure. The dried filtrate was resuspended in 250 }xl 70% ethanol and regarded as 
the soybean extract. 
3.2. High Performance Liquid Chromatography (HPLC) analysis of soybean 
extracts 
HPLC was used to determine the presence and the quantities of isoflavones in 
the 19 soybean extracts. 5 major isoflavones in soybean including daidzin, glycitin, 
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genistin, daidzein and genistein were selected for measurement. 
3.2.1. Preparation of soybean extracts for HPLC analysis 
50 \i\ of fully homogenized extract from each soybean sample was diluted with 
200 \i\ 70% ethanol and passed through the 0.45 \xm filter (Millipore). The filtrate was 
transferred into the HPLC vial (Hewlett-Packard) for analysis. 
3.2.2. HPLC analysis 
The HPLC analysis protocol was previously described by Achouri, A. (127) 
Briefly, a C18-YMC-Pack ODS AM (5 |im, 25 cm x 4.6 mm) column was used for the 
chromatographic separation. The column was rinsed with 20% methanol until the 
pressure stabilized. The column temperature was held constant at 22 °C in the thermal 
chamber controller. Elution was carried out at a flow rate of 1 ml/min with the 
following solvent system: A: acetonitrile, B: 0.2% trifluoroacetic acid (TFA). After 
injection of 20 |xl sample, the system was maintained at 15% A for 5 minutes, then 
increased to 30% in 10 minutes and held for 10 minutes, and then increased to 50% 
within 10 minutes and held for another 10 minutes. At the end of the 45 minutes, the 
system was recycled back to 15% A and held at that level for 10 minutes for a total 
run of 60 minutes per sample. Eluted isoflavones were monitored with UV at 254 nm. 
The HPLC analysis of each soybean extract was performed in triplicate and the peak 
areas was taken for calculation of isoflavone quantities. The standards of the 5 
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selected isoflavones and the flavone were also analyzed with the same protocol for 
calibration. 
3.3. Preparation of 5 human cancer cell lines for anti-proliferation assay 
3.3.1. Thawing of the cryopreserved stock of cell lines 
Five human cancer cell lines including A549 (121), K-562 (122)，PC-3 (122)， 
MCF7 (121) and MG-63 (124) were used to test the anti-proliferation effects of 
various soybeans on different cancer cell lines. The frozen stocks of these cell lines 
were obtained from Prof. M.C. FUNG'S laboratory, and they were thawed as 
described by Phelan, M. C. (129). In brief, the stock was taken out from the liquid 
nitrogen freezer and warmed at 37 °C water bath immediately. The stock was agitated 
until the content was fully melted, and the cells were transferred to 9 ml 3 7 � C 
completed culture medium. The content was centrifuged at 150 g for 10 minutes. The 
supernatant was removed with the cell pellet resuspended in 10 ml 37 °C completed 
culture medium. The culture was transferred to a 75 cm^ culture flask (Nunc). The 
above procedures were performed in sterilized environment, and the thawed culture 
was incubated at 37 °C incubator with 95% humidity and 5% CO2. 
3.3.2. Maintaining of cell lines 
Among the 5 cell lines, A549, PC-3, MCF7 and MG-63 were adherent cell lines 
and K-562 was suspension cell line. 
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For the adherent cell lines, the passaging of cells was performed by trypsinization 
when the culture reached 70% confluent. The protocol described by Ricardo R. was 
employed with minor modifications (130). Briefly, the medium was removed and the 
culture was washed with 5 ml DPBS for 3 times. A total of 2 ml trypsin: DPBS 
solution (volume: volume = 1:9) was added into the flask, and the culture was then 
incubated at 37 °C for 2 minutes. When the cells detached, 8 ml of 3 7 � C completed 
culture medium was added, and the cell density was then determined by the 
haemocytometer. To maintain a 10 ml culture with density of 2x10)4 cells/ml, the 
calculated amount of cells was transferred with the fresh completed culture medium to 
a new culture flask. All the procedures were performed in sterilized environment, and 
the passaged culture was incubated at 37 °C incubator with 95% humidity and 5% 
CO2. 
For the suspension cell K-562, the passaging of culture was performed when the 
cell density reached 2x10^ cells/ml. To maintain a 10 ml culture, the calculated 
amount of cells with fresh completed culture medium was transferred to a new culture 
flask to maintain a cell density of 2x1 O* cells/ml. The procedures were performed in 
sterilized environment, and the passaged culture was incubated at 37 °C incubator 
with 95% humidity and 5% CO2. 
3.3.3. Anti-proliferation test with MTT assay 
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The anti-proliferative effects of the soybean extracts were studied on each of the 
5 cancer cell lines by MTT assay. ED50 was used to compare the anti-proliferation 
potencies of the given soybean lines, and the lower value represents the higher 
potency. 
ED50 in the project refers to the concentration of crude soybean extract which 
can inhibit 50% proliferation of cells in the MTT assays. The lower the ED50, 
indicates the higher the potency. The unit of the ED50 in the project is weight (gram) 
of raw soybean materials per 1 ml assay volume. 
The assay was performed as described by Frey, R. S. (131) with minor 
modifications. Protocol for adherent and suspension cell lines was slightly different. 
For adherent cell lines, in brief, the cells were harvested by trypsinization as 
mentioned above. The cell density was determined by haemocytometer, and the 
density was adjusted to 2x1 O* cells/ml by 37 °C fresh completed culture medium. 
2x10^ cells, thus 100 i^l of density-adjusted culture were transferred to each well of 
the flat-bottomed 96-well microtiter plate (Nunc). The cells were allowed to stabilize 
in 37 °C incubator with 95% humidity and 5% CO2 overnight. On the following day, 
100 of 37 °C fresh completed culture medium was transferred into each well of a 
new round-bottomed 96-well microtiter plate (Nunc). 5 |il of the soybean extract and 
95 fxl of 37 °C fresh completed culture medium were added into the wells of first 
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column in triplicate. The content was fully homogenized and then two-fold serial 
diluted with the completed culture medium in succeeding wells. The serial diluted 
soybean extracts were transferred to the corresponding wells in the flat-bottomed 
96-well microtiter plate. The cells were treated with soybean extracts from 
concentration of 87.5 mg/ml to 85.4 ^ig/ml for 4 cell cycles in 3 7 � C incubator with 
95% humidity and 5% CO2. 
MTT assay was performed after the induction. 20 of 5 mg/ml MTT solution 
was added into each well of flat-bottomed 96-well microtiter plate. The cells were 
further incubated at 37 °C incubator with 95% humidity and 5% CO2 for 3 hours to 
allow the uptake of MTT compound. After 3 hours of incubation, the medium was 
removed completely by suction. 100 fxl of DMSO was added into each well, and the 
content was homogenized. The color intensity was determined by measuring the 
absorbance at 570 run with microplate reader. The data was used for construction of 
dose-response curve and determination of ED50 by the software GraphPad Prism 5.0. 
For K-562 cell line, 100 \i\ of 37 °C fresh completed culture medium was 
transferred into each well of a round-bottomed 96-well microtiter plate. 5 of the 
soybean extract and 95 |j,l of 37 °C fresh completed culture medium were added into 
the wells of first column in triplicate. The content was fully homogenized and then 
two-fold serial diluted with the completed culture medium in succeeding wells. On 
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the other hand, the cells density of K-562 culture was determined by haemocytometer 
and then adjusted to 2x10. cells/ml with 37 °C fresh completed culture medium. 2x10^ 
cells, thus 100 |xl of density-adjusted culture were transferred to each well of the plate 
with serial diluted soybean extract. The cells were treated with soybean extracts from 
concentration of 87.5 mg/ml to 85.4 |ig/ml for 4 cell cycles in 37 °C incubator with 
95% humidity and 5% CO2. 
MTT assay was performed after induction. 20 [i\ of 5 mg/ml MTT solution was 
added into each well of the plate, and the cells were incubated at 37 °C incubator with 
95% humidity and 5% CO2 for 3 hours to allow the uptake of MTT compound. After 
3 hours of incubation, the plate was centrifuged at 200 g for 7 minutes at room 
temperature. The medium was then carefully and completely removed by suction. 
100 jil of DMSO was added into each well, and the content was homogenized. The 
color intensity was determined by measuring the absorbance at 570 nm with 
microplate reader. The data was used for construction of dose-response curve and 
determination of ED50 by the software GraphPad Prism 5.0. 
3.4. Statistics 
Specific statistical analysis was performed on the data to verify the relationship 
between the factors investigated by the software GraphPad Prism 5.0. 
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4. Results 
4.1. Preparation of soybean extracts 
Each of the soybean sample was extracted with the protocol mentioned above 
and the calculated concentrations of the soybean extract after extraction were 4.375 
gram raw soybean material per ml and that of 2-phenylchromone was 400 j.ig/ml. The 
extracts were stored at -20�C for further analysis. 
4.2. HPLC analysis of 5 selected isoflavones in 19 soybean samples 
The total amount of 5 selected isoflavones, namely daidzin, glycitin, genistin, 
daidzein and genistein, in the 19 soybean samples were compared by HPLC 
(Methodology 3.2). Standard curves of 5 selected isoflavones and the standard curve 
for internal control 2-phenylchromone (Methodology 3.1) was produced by the 
protocol in Methodology 3.2. All the standard curves were presented in Appendix 8.1. 
After extraction, each soybean sample was analyzed by HPLC in triplicate 
(Fig.4.2.2) (Methodology 3.2). The data was adjusted with the internal control for the 
variations in extraction efficiencies between samples (Appendix 8.1.2). The 
concentration of each selected isoflavone was determined from the corresponding 
standard curves with internal control adjusted data (Appendix 8.1.2). 
Results from HPLC indicate that all the 5 selected isoflavones can be detected in 
all 19 soybean samples (Table 4.2.1). Both the contents and compositions of 5 
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selected isoflavones varies among the soybeans (Table 4.2.1 - Table 4.2.3). 
The contents of each and the total amount of selected isoflavones in 19 soybean 
samples are tabulated in Table 4.2.1. The average of sum of selected isoflavones in the 
soybeans is 3424.65 |xg per gram of soybean. The average content for each of selected 
isoflavone is 1222.0 |ig per gram for daidzin, 214.39 |j-g per gram for glycitin, 
1940.37 i^g per gram for genistin, 28.32 i^g per gram for daidzein and 19.57 ^g per 
gram for genistein. 
The composition of 5 selected isoflavones among the 19 soybean samples is 
summarized in Table 4.2.2, and the general composition of 5 selected isoflavones 
among the 19 soybean samples is presented in Fig.4.2.1. In the soybean samples, 
genistin and daidzin are found to be the major isoflavones. They contribute around 
56% and 35% of detected isoflavones, respectively. Glycitin is the prevalent 
isoflavone in soybeans, responsible for around 8%. Daidzein and genistein can be 
rarely found in the given soybean samples. They together contribute around 1% of 
sum of selected isoflavones. 
The content and composition of selected isoflavones shows a large variation in 
the soybeans. The variations are summarized in Table 4.2.3. The highest and lowest 
content of sum of selected isoflavones differs by 7.79 folds. DOS (H8525, irrigated) 
possesses the highest content of sum of selected isoflavones which is 6003.65 jig per 
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gram of soybean, compare with DOl (H8053, non-irrigated) containing the lowest 
content 770.88 |a,g per gram of soybean. 
Concerning individual isoflavone, in daidzin, the highest and lowest content is 
possessed by DOS and DOl, which are 2686.03 |a.g per gram and 286.77 jig per gram, 
respectively. Concerning the composition, DOS has the highest percentage of daidzin 
which is 44.74%, and D16 has the lowest that is 25.71%. 
For glycitin, the highest and lowest content is possessed by D13 (H8020, 
non-irrigated) and D17 (HK8596, non-irrigated), which are 299.23 jig per gram and 
79.77 }xg per gram, respectively. Concerning the composition, DOl has the highest 
percentage of glycitin which is 22.05%, and D04 (H8110，irrigated) has the lowest 
that is 4.17%. 
For genistin, the highest and lowest content is possessed by D04 and DOl, which 
are 3091.22 ixg per gram and 301.93 \ig per gram, respectively. Concerning the 
composition, D16 (HK8590, irrigated) has the highest percentage of genistin which is 
65.74%, and DOl has the lowest that is 39.17%. 
For daidzein, the highest and lowest content is possessed by D13 and D17, which 
are 67.4 ^g per gram and 3.47 jig per gram, respectively. Concerning the composition, 
D15 has the highest percentage of daidzein which is 1.5%, and D17 has the lowest 
that is 0.36%. 
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For genistein, the highest and lowest content is possessed by DOS and D09 
(HK8597, non-irrigated), which are 34.89 |ig per gram and 3.15 ng per gram, 
respectively. Concerning the composition, D15 (HK8590, irrigated) has the highest 
percentage of genistein which is 0.88%, and D09 has the lowest that is 0.36%. 
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The average content of selected isoflavone in each soybean 
sample ()ig/g) 






286.77 170.00 301.93 5.51 6.68 770.88 士 12.71 
D02 1251.24 177.75 1782.12 18.67 20.67 3250.44 士 11.28 
DOS 
H8110 
1446.26 261.57 2468.66 21.24 20.37 4218.11 ±36.66 
D04 2128.90 229.32 3091.22 24.22 20.76 5494.42 ±96.52 
D05 
H8301 
812.78 210.34 1365.47 19.38 14.48 2422.43 士111.6 
D06 1886.57 284.26 2661.09 27.38 20.38 4879.68 ±171.1 
D07 
H8525 
1172.88 185.82 2166.98 20.20 16.64 3562.52 ±27.52 
D08 2686.03 267.53 2964.40 50.80 34.89 6003.65 ±598.2 
D09 
HK8597 
298.95 133.79 431.67 6.37 3.15 873.92 士 28.47 
DIO 913.22 203.34 1647.63 21.85 17.95 2803.99 士 25.34 
Dll 
H8007 
1084.27 221.64 1889.86 31.29 24.88 3251.94 ±173 
D12 957.34 214.83 1824.07 24.80 18.81 3039.85 ±76.28 
D13 
H8020 
1719.44 299.23 2602.47 67.40 30.41 4718.95 ±203.3 
DM 1694.96 236.68 2324.75 53.87 29.10 4339.37 ±301.5 
D15 
HK8590 
370.84 171.20 727.08 19.47 11.44 1300.03 ±103.3 
D16 1025.52 258.40 2622.17 52.37 30.42 3988.88 ±16.1 
D17 
HK8596 
383.90 79.77 494.57 3.47 5.90 967.61 士 6.81 
D18 1428.54 194.02 2484.28 27.68 16.70 4151.22 ±21.42 
D19 U 1669.65 273.85 3016.67 42.17 28.12 5030.47 士 57.13 
Average content 1222.0 214.39 1940.37 28.32 19.57 3424.65 
The green color highlights the soybean with highest amount of indicated isoflavone. 
The blue color highlights the soybean with least amount of indicated isoflavone. 
The soybean extracts were analyzed by HPLC to determine the quantity of 5 selected 
isoflavones. Each extract was analyzed for triplicate, and the data in the table is the 
average with standard derivation. n=3 
4 1 





The percentage of selected isoflavones in soybean sample (%) 
Daidzin Glycitin Genistin Daidzein | Genistein 
DOl 
H8053 
37.20 22.05 39.17 0.71 0.87 
D02 38.49 5.47 54.83 0.57 0.64 
DOS 
H8110 
34.29 6.20 58.53 0.50 0.48 
D04 38.75 4.17 56.26 0.44 0.38 
D05 
H8301 
33.55 8.68 56.37 0.80 0.60 
D06 38.66 5.83 54.53 0.56 0.42 
D07 
H8525 
32.92 5.22 60.83 0.57 0.47 
D08 44.74 4.46 49.38 0.85 0.58 
D09 
HK8597 
34.21 15.31 49.39 0.73 0.36 
DIO 32.57 7.25 58.76 0.78 0.64 
Dl l 
H8007 
33.34 6.82 58.11 0.96 0.77 
D12 31.49 7.07 60.01 0.82 0.62 
D13 
H8020 
36.44 6.34 55.15 1.43 0.64 
D14 39.06 5.45 53.57 1.24 0.67 
D15 
HK8590 
28.53 13.17 55.93 1.50 0.88 
D16 25.71 6.48 65.74 1.31 0.76 
D17 
HK8596 
39.67 8.24 51.11 0.36 0.61 
D18 34.41 4.67 59.84 0.67 0.40 
D19 U 33.19 5.44 59.97 0.84 0.56 
Average percentage 35.12 7.81 55.66 0.82 0.6 
The soybean samples were extracted, and then analyzed by HPLC to determine the 
quantity of 5 selected isoflavones. Each extract was analyzed in triplicate. The 
percentage of each selected isoflavone is calculated by dividing the content of 
selected isoflavone by the sum of selected isoflavone in the same soybean sample. 
The average percentage is calculated by averaging the percentages of specified 
isoflavone in 19 soybean samples. 
Table 4.2.3 The summary about the variations in soybean samples 
Highest Lowest Folds 
Soybean Content Soybean Content Differences 
Line ( _ / Line (^ig/g)/ between 
Percentage Percentage Highest and 
(%) (o/o) Lowest 
Sum of 5 DOS 6003.65 DOl 770.88 7.79 
Selected 
Isoflavones 
Daidzin DOS 2686.03 DOl 286.77 9.37 
Glycitin D13 299.23 D17 79.77 3.75 
Genistin D04 3091.22 DOl 301.93 10.24 
Daidzein D13 67.40 D17 3.47 19.42 
Genistein D08 34.89 D09 3.15 11.08 
Daidzin D08 44.74 D16 25.71 1.74 
Percentage 
Glycitin DOl 22.05 D04 4.17 5.29 
Percentage 
Genistin D16 65.74 DOl 39.17 1.68 
Percentage 
Daidzein D15 1.50 D17 0.36 4.17 
Percentage 
Genistein D15 0.88 D09 0.36 2.44 
Percentage 
4 3 
The isofla\ ones composition 
in 19 soybean samples 
Daidzin • Glvcitin • Genistm • Daidzem and GeiiLstem 
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Fig,4.2.1 The isoflavones composition in 19 soybean samples The 19 soybean 
extracts were used for analyzed of the quantities of 5 selected isoflavones by HPLC. 
The percentages of each selected isoflavone in 19 soybean samples are averaged to 
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Fig.4.2.2 The HPLC analysis of 5 selected isoflavones in soybean DOl The 19 
soybean extracts were used for analyzed of the amounts of 5 selected isoflavones in 
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4.3. Comparison of sum of 5 selected isoflavones among the parent soybean and 
lines harvested from irrigated land 
In the project, 9 soybean lines derived from the parent D19 (U, irrigated) were 
given for analysis of isoflavone contents. As the parent soybean has no drought 
tolerant counterpart, the isoflavone content of beans harvested from irrigated land was 
used for comparison by one-way ANVOA followed by Tukey test. 
The contents of sum of selected isoflavones vary among the soybean parent and 
lines from irrigated land (Fig.4.3.1). Among the 9 lines, DOS (H8525, irrigated) 
produces significantly more selected isoflavones than the parent, which is about 19% 
more. The other 2 lines, D04 (H8110, irrigated) and D06 (H8301, irrigated), give 
comparable amount of selected isoflavones to D19，while the differences are not 
significant. For the remaining 6 lines, they all produce significantly less amount of 
selected isoflavones than the parent. On average they produce 40% less selected 
isoflavones than D19. 
The soybeans can roughly be divided into 3 groups when only the 9 lines are 
compared (Fig.4.2.1). D02 (H8053, non-irrigated), DIO (HK8597, irrigated) and D12 
(H8007, irrigated) give relatively less amount of sum of selected isoflavones, and the 
contents they produce have no significant difference. D14 (H8020, irrigated), D16 
(HK8590, irrigated) and D18 (HK8596, irrigated) produce relatively more than the 
4 6 
previous 3 lines, and there are no significant difference in production among these 3 
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Soybean Sample 
Fig.4.3.1 Sum of 5 selected isoflavones in soybean samples harvested from 
irrigated land The soybean samples were extracted and then analyzed by HPLC to 
determine the quantities of 5 selected isoflavones. The quantities of selected 
isoflavones in soybeans harvested from irrigated land are compared by one-way 
ANOVA with Tukey test. Soybean samples with identical letter have no significant 
difference in sum of 5 selected isoflavones. The data in the figure are mean 士 S.E.M， 
n=3. *，p < 0.05; NS, difference not significant as compared with sum of selected 
isoflavones in D19. 
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4.4. Comparison of sum of 5 selected isoflavones among the soybean lines 
harvested from non-irrigated land 
For each of the 9 lines, soybean harvested from the non-irrigated land was also 
provided for analysis of isoflavone contents. The quantities of selected isoflavones in 
these soybeans were compared by one-way ANVOA followed by Tukey test. 
The contents of sum of selected isoflavones vary among soybeans from 
non-irrigated land (Fig.4.4.1). Among the 9 lines, 6 of them produced significantly 
different amounts of selected isoflavone. The contents of selected isoflavones in other 
3 lines DOl (H8053, non-irrigated), D09 (HK8597, non-irrigated), D17 (HK8596, 
non-irrigated) were relatively lower and with no significant difference among these 3 
lines. D15 (HK8590, non-irrigated) producd relatively less selected isoflavones, while 
DOS (H8301, non-irrigated) produced the moderate amount. 4 lines, DOS (H8110, 
non-irrigated), D07 (H8525, non-irrigated), Dl l (H8007, non-irrigated) and D13 
(H8020, non-irrigated) have relatively more selected isoflavones. D13 produces the 
highest sum of selected isoflavones in beans from drought land that is 4718.95 ^g per 








/ < > � � < ^ � b 
Soybean Sample 
Sum of 5 selected isoflavones in 









0) c o 
b 
d e 
Fig.4.4.1 Sum of 5 selected isoflavones in soybean samples harvested from 
non-irrigated land Soybean samples were extracted and then analyzed by HPLC to 
determine the quantities of the 5 selected isoflavones. The quantities in soybeans 
harvested from non-irrigated land are compared by one-way ANOVA with Tukey test. 
Soybean samples with identical letter have no significant difference in sum of 5 
selected isoflavones. The data in the figure are mean 士 S.E.M, n=3. 
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4.5. Comparison of selected isoflavones among the parent soybean and lines 
harvested from irrigated land 
Contents of 5 selected isoflavones daidzin, glycitin, genistin, daidzein and 
genistein in soybean lines harvested from irrigated land are compared to those in 
parent soybean D19 by one-way ANOVA followed by Tukey test. 
The quantities of daidzin produced by different soybean samples vary among the 
9 soybean lines (Fig.4.5.1a). 
Comparing with the parent, D06 (H8301, irrigated), D14 (H8020, irrigated) and 
D18 (HK8596, irrigated) producd similar amounts of daidzin to D19 (U, irrigated). 
D04 (H8110, irrigated) and DOS (H8525, irrigated) produce significantly more 
daidzin than the parent, which is about 27% and 61% more，respectively. For the 
remaining 4 soybeans D02 (H8053, irrigated), DIO (HK8597, irrigated), D12 (H8007, 
irrigated) and D16 (HK8590, irrigated), they all contain significantly less daidzin than 
the parent. On average, they produce about 38% less daidzin than D19. 
Comparing the contents of daidzin among the 9 lines from irrigated land 
(Fig.4.5.1a), DIO produces the least amount. D12 and D16 contained comparable 
amount of daidzin to DIO, and the productions in these 3 varieties have no significant 
different. D02 and D18 give slightly more daidzin, while D04, D06, D14 and DOS 
contain even more. DOS has the highest content of daidzin which is 2686 i^g per gram 
5 1 
ofsoybean. 
The quantities of glycitin produced by different soybean samples show a 
relatively small variation among 5 selected isoflavones (Fig.4.5.1b). 
Comparing with the parent, D06, DOS and D16 are producing similar amounts of 
glycitin to D19. For the remaining 6 soybeans D02，D04, DIO, D12, DM and D18, 
they all contain significantly less glycitin than the parent. On average, they produce 
about 24% less glycitin than D19. 
Comparing the contents of glycitin among the 9 lines from irrigated land 
(Fig.4.5.1b)，D02 gives the lowest content. D02, DIO and D18 produce relatively less 
glycitin. D04, D12 and D14 give slightly more glycitin, while D06, DOS and D16 
produce even more. D06 has the highest content of glycitin which is 284.3 |xg per 
gram of soybean. 
The quantities of genistin produced by different soybean samples vary among 9 
lines (Fig.4.5.1c). 
D04，D06 and DOS produced similar amounts of genistin to the parent D19. The 
remaining 6 lines give significantly less genistin than the parent. D02, DIO and D12 
on average produce 42% less genistin, while D14, D16 and D18 on average produce 
18% less than D19. 
Comparing the contents of genistin among the 9 lines from irrigated land 
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(Fig.4.5.1c), D04 and DOS contain relatively high and not significantly different 
contents of genistin, with D04 has the highest content 3091 ^ g per gram of soybean. 4 
lines D06, D14, D16 and D18 give slightly less genistin. The contents of genistin in 
these 4 lines give no significant differences. The remaining 3 lines contain relatively 
fewer amounts, with D02 contains the least amount of genistin. The contents of 
genistin in these 3 lines have no significant difference. 
The quantities of daidzein produced by different soybean samples show a 
relatively small variation among the selected isoflavones (Fig.4.5.1d). 
Comparing with the parent, DOS produces similar content of daidzein to D19 
with no significant difference. D14 and D16 are producing significantly more 
daidzein than the parent, which is on average about 23% more. For the remaining 6 
soybeans D02, D04, D06, DIO, D12 and D18, they all contain significantly less 
daidzein than the parent D19. On average, they produce about 42% less daidzein than 
the parent. 
Comparing the contents of daidzein among the 9 lines from irrigated land 
(Fig.4.5.1d), D02 produces the least amount. 6 lines D02, D04, D06, DIO, D12 and 
D18 have similar content of daidzein, and they have significantly less daidzein than 
the others. DOS, D14 and D16 produce more daidzein, with D14 has the highest 
content of daidzein which is 53.87 per gram of soybean. 
5 3 
The quantities of genistein produced by different soybean samples show a 
relatively small variation among the 5 selected isoflavones (Fig.4.5.1e). 
3 soybean lines DOS, D14 and D16 are producing comparable amounts of 
genistein to the parent D19. The contents of genistein in 3 lines have no significant 
differences to D19. The remaining 6 lines contain significantly less genistein than the 
parent. D02, D04, D06, DIO, D12 and D14 on average produce 32% less genistein 
than the parent D19. 
Comparing the contents of genistein among the 9 lines from irrigated land 
(Fig.4.5.1e), D18 has the least amount of genistein. 6 lines, D02, D04, D06, DIO, D12 
and D14, contain similar amounts of genistein. DOS, D14 and D16 produce relatively 
more genistein, with DOS has the highest content 34.98 |ig per gram of soybean. 
These 3 varieties have no significant differences in contents of genistein. 
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Fig.4.5.1 Content of 5 selected isoflavones in soybean samples harvested from 
irrigated land The soybean samples were extracted, and then analyzed by HPLC to 
determine the contents of 5 selected isoflavones. Contents of (a) daidzin, (b) glycitin, 
(c) genistin, (d) daidzein, and (e) genistein in soybeans are compared by one-way 
A N O V A followed by Tukey test. Soybean samples with identical letter have no 
significant difference in sum of 5 selected isoflavones. The data in the figure are mean 
± S.E.M, n=3. 
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4.6. Comparison of selected isoflavones among the soybean parent and lines 
harvested from non-irrigated land 
Contents of 5 selected isoflavones daidzin, glycitin, genistin, daidzein and 
genistein in soybean varieties harvested from non-irrigated land are compared by 
one-way A N O V A followed by Tukey test. 
The quantities of daidzin produced by different soybean samples vary among the 
9 soybean lines (Fig.4.6.1a). Among the lines, DOl (H8053, non-irrigated) produces 
the least amount. 4 lines DOl, D09 (HK8597, non-irrigated), D15 (HK8590, 
non-irrigated) and D17 (HK8596, non-irrigated) contain comparable amount of 
daidzin, and the productions in these 4 lines have no significant different. The daidzin 
contents in D07 (H8525, non-irrigated) and Dll (H8007, non-irrigated) are not 
significantly different. They produce more daidzin than DOS (H8301, non-irrigated), 
but less than D03 (H8110, non-irrigated) and D13 (H8020, non-irrigated). D13 has the 
highest content of daidzin which is 1719 jig per gram of soybean. 
In glycitin, the quantities produced by different soybean samples vary among the 
9 lines (Fig.4.6.1b). D17 has the least content of glycitin. D09 produce slightly more, 
while DOl, D07 and D15 contain even more. The 3 lines have no significant 
differences in glycitin contents. D13 has 299.2 ^ig glycitin per gram of soybean which 
is the highest, followed by DOS, DOS and Dll. The later 2 possess glycitin contents 
5 8 
with no significant differences. 
The quantities of genistin produced by different soybean samples vary among 9 
lines (Fig.4.6.1c). In the 9 lines, D15, DOl, D09 and D17 produce comparable and 
relatively fewer amounts of genistin. D05 and Dll produce moderate amount of 
genistin, while DOS, D07 and D13 possess the relatively high content of genistin. D13 
has the highest content of 2602 [xg genistin per gram of soybean. 
The quantities of daidzein produced by different soybean samples show a 
relatively small variation (Fig.4.6.1d). Among the lines, D17 possesses the least 
amount of daidzein. DOl, D09 and D17 have similar contents of daidzein. They 
produce relatively little and no significant differences can be determined between 
their contents. 4 lines D03, D05, D07 and D15 produce more daidzein, and they have 
no significant differences in their daidzein contents. The highest content of daidzein is 
possessed by D13 which is 67.4 |ig per gram of soybean, followed by Dll. 
The quantities of genistein produced by different soybean samples vary among 
the lines (Fig.4.6.1e). 3 soybean lines DOl, D09 and D17 produce relatively less 
genistein. Their productions are comparable with D09 producing the least. D15, D05 
and D07 contain more genistein and the contents in later 2 have no significant 
difference. D03, Dll and D13 give the relatively high contents of genistein and D13 
is the highest that is 30.41 per gram of soybean. 
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Fig.4.6.1 Content of 5 selected isoflavones in soybean samples harvested from 
non-irrigated land The soybean samples were extracted, and then analyzed by HPLC 
to determine the contents of 5 selected isoflavones. Contents of (a) daidzin, (b) 
glycitin, (c) genistin，(d) daidzein, and (e) genistein in soybeans are compared by 
one-way A N O V A followed by Tukey test. Soybean samples with identical letter have 
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4.7. Comparison of sum of selected isoflavones among the soybeans harvested 
from irrigated land and non-irrigated land 
In each line, the contents of selected isoflavones in soybeans harvested from 
non-irrigated land and irrigated land are compared by paired Student's /-test. 
Among the 9 lines, 7 out of 9 do show a significant difference in isoflavone 
content when growing in different conditions (Fig.4.7.1). The soybeans grew on 
irrigated land on average produce 1.8 folds more isoflavones than their non-irrigated 
land counterpart. In certain line, the differences in isoflavone content can even up to 3 
folds, such as DOl (H8053, irrigated) and D02 (H8053, non-irrigated). 
In 2 lines, D11/D12 (H8007) and D13/D14 (H8020), the beans harvested from 
non-irrigated land produce slightly more isoflavones than the irrigated counterpart. 






Isoflavones production in soybeans harvested 
from non-irrigated land and irrigated land 
國 Harvested from non-irrigated land 
8000n 因 Harvested from irrigated land 
Fig.4.7.1 Isoflavone production in soybeans harvested from non-irrigated land 
and irrigated land The isoflavone contents of 9 pairs of soybean lines, with 1 parent 
soybean D19 were extracted and analyzed by HPLC to determine the quantities of 
selected isoflavones. With the same line, the sum of selected isoflavones between 
soybeans harvested from non-irrigated land and irrigated land are compared by paired 
Student's 广-test. The soybean samples in pairs belong to the same line. The samples 
labeled in odd number were harvested from non-irrigated land and labeled in even 
number were from irrigated land. The data in the figure are mean 士 S.E.M，n=3. *, p < 
0.05; **，p < 0 . 0 0 5， p < 0.0001 
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4.8. Determination of anti-proliferation abilities of 19 soybean samples 
4.8.1. Anti-proliferation test of ethanol and 2-phenylchromone 
As the cytotoxic ethanol and 2-phenylchromone (internal control) are present in 
the soybean extracts, the effects of these chemicals on proliferation of cell lines were 
determined as control experiments (Methodology 3.3.3) to ensure their presence will 
not affect the results. 
The anti-proliferation tests indicate that the concentration of ethanol and 
2-phenylchromone had no anti-proliferation effect on the 5 cancer cell lines are the 
same, which is 0.78% (Percentage of ethanol by assay volume) (Appendix 8.2.1), and 
that of 2-phenylchromone are 5.86 jxg/ml (Appendix 8.2.1). As the highest 
concentration of ethanol and 2-phenylchromone in the anti-proliferation assays are 
0.5% and 5 |xg/ml, respectively, the presence of these 2 chemicals in soybean extracts 
should not have any effect on proliferation of the 5 cell lines. 
4.8.2. Anti-proliferation activities of 19 soybean samples on 5 human cancer cell 
lines 
The anti-proliferation activities of the 19 soybeans were tested on 5 human 
cancer cell lines including the lung cancer (A549), the leukemia (K-562), the breast 
cancer (MCF7), the osteosarcoma (MG-63) and the prostate cancer (PC-3) by M T T 
assay (Methodology 3.3.3). Dose-response relationships were determined with the 
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calculation of ED50 (Appendix 8.2.2). 
Concerning a single cell line, the ED50 of different soybean samples varies (Table 
4.8.2.1). In A549, DOl (H8053, non-irrigated) is the most potent with an ED50 of 
13.64 mg/ml and D19 (U, irrigated) is the least potent giving an ED50 of 48.65 mg/ml. 
The average ED50 of soybean samples on A549 is 23.82 mg/ml. 
In K-562, D03 (H8110, non-irrigated) is the most potent with an ED50 of 6.79 
mg/ml and D19 is the least potent giving an ED50 of 22.37 mg/ml. The average ED50 
of soybean samples on K-562 is 13.01 mg/ml. 
In MCF7, D04 (H8110, irrigated) is the most potent with an ED50 of 10.02 
mg/ml and D02 (H8053, irrigated) is the least potent giving an ED50 of 29.85 mg/ml. 
The average ED50 of soybean samples on MCF7 is 23.82 mg/ml. 
In MG-63, DOS is the most potent with an ED50 of 2.01 mg/ml and D05 (H8301, 
non-irrigated) is the least potent giving an ED50 of 11.44 mg/ml. The average ED50 of 
soybean samples on MG-63 is 7.46 mg/ml. 
In PC-3, D04 is the most potent with an ED50 of 7.26 mg/ml, while DOS is the 
least potent giving an ED50 of 20.94 mg/ml. The average ED50 of soybean samples on 
PC-3 is 11.75 mg/ml. On average, there is a 3.7 folds difference between the lowest 
and highest ED50 among the 5 cell lines. 
The ED50 of the same soybean sample also varies crossing the 5 cell lines (Table 
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4.8.2.1). For example in D03, the ED50 for K-562 is 6.79 mg/ml and that of A549 is 
18.36 mg/ml. There is a 2.7 folds difference. The same phenomenon can also be 
observed in other soybean samples. 
To compare the anti-cancer potencies of 19 soybeans, the ED50S are ranked in 
ascending order. Within a cell line, 1 is the most potent and 19 is the least potent. For 
each soybean line, the ranks from each cell line are summed up as total rank. The 
soybean with the smallest total rank, which implies the generally high potencies 
across the 5 cell lines, will be considered as the most potent soybean line and vice 
versa. With such criteria, it is found that D03 is the most potent soybean line and the 
DOS is the least potent one (Table 4.8.2.2). 
The dose-response curves of soybean DOl on 5 cell lines are illustrated below, 
and the dose-response curves of D02-D19 on 5 cell lines are attached in Appendix 
8.2.2. 
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Fig.4.8.2.1 The anti-proliferation effect of DO 1 on 5 cancer cell line The (a) lung 
cancer cell line A549, (b) leukemia K-562, (c) breast cancer MCF7, (d) osteosarcoma 
MG-63 and (e) prostate cancer PC-3 was subjected to the soybean extract DOl 
induction from concentration of 87.5 mg/ml to 85.4 |xg/ml (amount of raw soybean 
materials per ml) in two-fold serial dilution manner for 4 cell cycles. M T T assay was 
performed at the end of induction. The data was collected for the dose-response 
analysis and determination of ED50. The data in the figure are mean 士 S.E.M，n=3. 
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ED50 of Soybean Extracts on Each Cell Line 










DOl 13.64 ±2.01 7.52 ±1.37 19.68 ±3.58 5.69 土 0.71 8.76 ±1.02 
D02 29.17 土2.64 12.15 ±0.32 29.85土 6.63 11.38 ±0.64 16.19 ±0.47 
D03 18.36 土 3.47 6.79 ±U1 13.47 ±1.42 2.01 ±0.02 10.69 ±1.14 
D04 21.06 ±3.25 8.36 土 0.89 10.02 ±0.84 6.78 ±1.24 7.26 ±3.50 
DOS 30.07土 6.13 21.90 ±0.35 26.38 ±1.98 11.44 ±0.42 20.94 ±0.45 
D06 21.04 ±0.91 13.08 土 1.84 15.18 土 1.41 7.51 ±0.19 10.63 ±0.35 
D07 14.87 ±1.67 16.56 ±1.42 18.54 ±3.25 6.00 ±0.78 7.60 土 0.31 
DOS 17.57 土 1.28 14.93 ±1.38 14.86 ±1.75 6.93 ±0.40 9.09 ±1.01 
D09 16.70 土 2.75 17.11 土 1.72 15.40 ±1.75 4.81 ±0.18 8.20 ±0.45 
DIO 19.97 ±2.62 14.21 ±2.26 19.52 ±3.67 8.22 ±0.37 10.88 ±0.31 
Dll 21.52 土 2.15 12.50 土 1.02 17.54 ±3.26 5.03 ±0.31 10.55 ±0.66 
D12 17.64 土 3.92 11.53 ±0.53 19.86 ±1.37 6.49 ±0.32 8.64 ±0.55 
D13 29.63 土2.93 11.02 土 0.13 18.72 土0.63 7.03 土0.31 12.06 ±1.12 
D14 23.92 士 0.78 11.18 ±0.26 14.33 ±0.66 6.92 ±1.85 11.44 ±0.31 
D15 29.87 土 2.72 9.91 土 1.38 20.68 土 0.43 11.38 ±0.04 13.15 ±1.67 
D16 23.51 ±0.53 10.94 ±0.38 12.89 土 1.13 8.41 ±0.55 10.85 ±0.10 
D17 32.99 土 1.20 13.50 ±2.68 22.33 ±0.42 9.18 ±0.33 18.47 ±2.45 
D18 22.36 ±1.54 11.56 土 0.21 12.04 ±0.41 6.62 ±0.43 13.63 ±1.90 
D19 48.65 土 1.66 22.37 ±0.42 13.59 ±1.05 9.83 ±2.53 14.26 ±0.32 
The green color highlights the soybean line with lowest ED50, thus highest potency. 
The blue color highlights the soybean line highest with ED50, thus lowest potency. 
The anti-proliferation assays for each soybean extract was performed for 3 times. 
ED50 was determined separately. The average of 3 ED50 was taken as the ED50 of 
particular soybean extract on specified cell line. The data in the figure are mean 土 
S.E.M, n=3. 
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Table 4.8.2.2 Rank of EDgns of soybean samples on 5 human cancer cell lines 
Rank of ED50 in corresponding cell line Sum of selected 
Soybean 
Line 






DOS 6 1 4 1 1 9 21 4218.11 士 36.66 
D04 9 3 1 8 1 2 2 5494.42 ±96.52 
DOl 1 2 14 4 5 2 6 770.88 士 12.71 
D09 3 17 9 2 3 34 873.92 士 28.47 
D07 2 16 11 5 2 36 3562.52 士27.52 
D12 5 8 15 6 4 38 • 3039.85 ±76.28 
Dll 10 11 10 3 7 41 3251.94 士 173 
D08 4 15 7 10 6 42 6003.65 ±598.2 
D16 12 5 3 14 10 44 3988.88 士 16.1 
D18 11 9 2 7 15 44 4151.22 士 21.42 
D M 13 7 6 12 47 4339.37 ±301.5 
D06 8 12 8 12 8 48 4879.68 ±171.1 
D13 15 6 12 11 13 57 4718.95 ±203.3 
mo 7 14 13 13 11 58 2803.99 ±25.34 
D15 16 4 16 17 14 67 1300.03 士 103.3 
D19 19 19 5 16 16 75 5030.47 ±57.13 
D02 14 10 19 18 17 78 3250.44 ±11.28 
D17 18 13 17 15 18 81 967.61 士 6.81 
DOS 17 18 18 19 19 91 2422.43 ±111.6 
The green color highlights the soybean line with lowest ED50, thus highest potency. 
The blue color highlights the soybean line highest with ED50, thus lowest potency. 
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4.9. Comparison of anti-proliferation potencies of 19 soybean samples with sum 
of selected isoflavones 
The sum of ED50 ranks (summed rank) of 19 soybean samples are arranged in 
ascending order, and analyzed in pair with corresponding sum of selected isoflavones 
for possible relationship between anti-proliferation activities and quantities of 
isoflavones. 
As the summed rank of 19 soybean samples increase, the sum of selected 
isoflavones fluctuate (Fig.4.9.1). Concerning the 8 soybean samples D06 (H8301, 
irrigated), D13 (H8020, non-irrigated), DIO (HK8597. irrigated), D15 (HK8590, 
non-in-igated), D19 (U，irrigated), D02 (H8053, irrigated), D17 (HK8596，irrigated) 
and DOS (H830K non-irrigated), they show a gradual increasing in ranking. Among 
these 8 samples, 4 of them (D06. D13. DIG and D15) do show the inverse 
proportional relationship between ranking and sum of selected isoflavones. However, 
this relationship cannot be established when D19, D02, and D05 are also considered. 
In addition, DOl (H8053, non-irrigated) and D09 (HK8597，non-irrigated) had 
significantly low content of selected isoflavone, yet they ranked at the and the 
in anti-proliferation activities. D06, D13 and D19 had comparable amount, but they 
give 3 different rankings. The sum of selected isoflavones varies in the ascending 
summed rank, and no generalized pattern can be concluded. 
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The sum of rank of EDSOs and sum of 
selected isoflavones of 19 soybean samples 
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Fig.4.9.1 The sum of rank of ED50S and sum of selected isoflavones of 19 soybean 
samples The ED50S of soybean samples on 5 cell lines are ranked and the rankings are 
summed up. The sum of ED50S ranks are arranged in ascending order, paired with 
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4.10. Comparison of anti-proliferation potencies of 19 soybean samples 
The anti-proliferation potencies of 19 soybean samples are compared by the 
average ED50 rank (average rank) with use of one-way A N O V A followed by Tukey 
test. 
Comparing the average rank among 19 soybeans, the variation is significant 
(Fig.4.10.1). Among the 19 soybean samples, 3 have relatively lower average rank. 
They are DOl, D03 and D04, with D03 is the lowest and the most potent. 10 samples 
(D06-D12, D14, D16 and D18) give comparable average rank. D13 and D15 give 
slightly higher average rank than the 10 samples, while D02, D05, D17 and D19 
possessed relatively higher average rank. The average ranks of these 4 soybeans have 
no significant difference and D05 had the highest average rank, meaning it is the least 
potent. 
Comparing the average ranks，significant difference can be observed in the 
extracts prepared from 4 lines including D01/D02 (H8053), D05/D06 (H8301), 
D15/D16 (HK8590) and DI7/D18 (HK8596) (Fig.4.10.1). D02, D06, D16 and D18 
were harvested from irrigated land and their counterparts were from non-irrigated 
land. Besides D02，the other 3 soybeans from irrigated land give significantly lower 
average ranks than their non-irrigated land coimterparts. 
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The average rank of ED50 of 19 
soybean samples 
Fig.4.10.1 The average rank of ED50 of 19 soybean samples The average rank of 
ED50 of 19 soybean samples are compared with one-way A N O V A followed by Tukey 
test. Soybean samples with identical letter have no significant difference in the 
average rank of ED50. The samples labeled in odd number were harvested from 
non-irrigated land and labeled in even number were from irrigated land. The data in 
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4.11. Anti-proliferation effect of individual isoflavones on 5 cancer cell lines 
The relationship between the presence of 5 selected isoflavones and degree of 
anti-proliferation activities is verified by the correlation analysis. 
The presence of daidzin and genistin in the soybean extracts is found to be 
correlated to the anti-proliferation activities of soybean extracts on MCF7 cell line 
(Fig.4.11.1a-c) The correlation is inversely proportional, thus the higher concentration 
of these isoflavones in the extracts will give a lower ED50 in anti-proliferation assay 
on MCF7 cell line. No other correlations can be determined from other cancer cell 
lines and the isoflavones. 
Figures for correlation analysis on total amount of selected isoflavones, daidzin 
and genistin on MCF7 cell line are selected for illustration. The figures for correlation 
analysis on total amount of selected isoflavones and individual isoflavones on 5 
cancer cell lines are presented in Appendix 8.3. 
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Correlation between Daidzin 
and ED50S on MCF7 cell line 
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Correlation between Genistin 
and EDSOs on MCF7 cell line 
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Fig.4.11.1 The correlation between selected isoflavones and EDsos on MCF7 cell 
line The (a) sum of selected isoflavones, (b) content of daidzin, (c) content of genistin 
was analyzed against the corresponding EDsoS on MCF7 cell line by correlation 
analysis. The data in the figure are mean 土 S.E.M, n=3. p for (a): 0.0081; p for (b): 
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5. Discussion 
5.1. Extraction of 19 soybean samples 
In the project, for each of the 19 soybean samples, 5 grams of soybean were 
provided by Prof. H.M. LAM. Concerning the limited amount, 2 grams of soybean 
were used in extraction. However, it should be noted that, even with random sampling, 
extracts from 2 grams of soybean from a single harvest may not be able to truly 
represent the whole picture of the characteristics of a particular soybean, but just a 
rough outline. With the help of internal control, differences in extraction efficiencies 
were adjusted. Therefore, data in the project can be, and is used to estimate the 
quantities and composition of the 5 selected isoflavones. Anti-proliferation assays 
were performed and EDsos are also determined. However, for a more accurate 
comparison, repeating extractions and analysis with larger quantities of soybean, for 
example 50 grams is suggested. The practice can reduce the variations in the results 
due to small extraction amount, and more refined extraction/ purification can be 
possible for more precise determination of the isoflavone contents of the soybean 
samples. 
5.2. Determination of quantities of selected isoflavones in 19 soybean samples by 
HPLC analysis 
A total of 19 soybean samples including 9 soybean lines derived from the given 
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parent soybean were studied in the project. For each of the line, soybeans harvested 
from irrigated land and non-irrigated land were provided. High performance liquid 
chromatography (HPLC) was used to analyze the isoflavone contents of these 19 
soybean samples. 5 isoflavones namely daidzin, glycitin, genistin，daidzein and 
genistein were selected for analysis as they have been reported for significant 
bioactivities including anti-cancer and anti-osteoporosis activities (94-111). They also 
represent the major isoflavones found in the soybeans (88-89). The internal control, 
2-phenylchromone was added during extraction to verify the fluctuation in extraction 
efficiencies and the quantities of isoflavones can therefore be measured and 
compared. 
The quantities of selected isoflavones in the soybean samples are found to have a 
large variation (Table 4.2.1, Table 4.2.3). The average content of selected isoflavones 
in 19 soybeans is 3424.65 jig per gram of soybean. 3 soybean samples possess less 
than 1,000 jxg selected isoflavones per gram of soybean, while another 3 lines have 
more than 5,000 |xg per gram. The highest and lowest amount of isoflavones is given 
by DOl (H8053, non-irrigated) and D08 (H8525 irrigated), containing 770.88 ^ ig per 
gram of soybean and 6003.65 jag per gram of soybean, respectively. 
The HPLC results indicate that the parent soybean D19 (U, irrigated) yielded 
5030.47 ng selected isoflavone per gram of soybean, which ranked at the among 
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the 19 tested soybean samples (Table 4.2.1). It implies that only 2 soybean lines can 
produce more selected isoflavones than D19, and the remaining 16 lines are less 
productive in those selected isoflavones. Furthermore, the average quantity of selected 
isoflavones in the 9 varieties is 3335.4 |ig per gram of soybean, which is about 34% 
less than the parent line (Table 4.2.1). 
From the above, it can be concluded that in terms of isoflavone production, 
generally the produced lines (D01-D18) are worse than the parent. However it should 
be noted that, particularly for daidzin and daidzein, DOS and D13 (H8020, 
non-irrigated) could produce about 60% more than the parent D19, respectively 
(Table 4.2.1). 
Besides the quantities, the composition of isoflavones in the given 19 soybeans 
also shows an obvious derivation (Table 4,2.2). The percentage of particular 
isoflavone shows a 1.68 to 5.29 folds difference, depending on the isoflavone 
concerned. 
The above information is important as it has been reported that, soybeans possess 
various kinds of bioactivities including anti-cancer (94-106) and anti-osteoporosis 
activities (107-111). The bioactivities of soybeans, particularly in anti-osteoporosis, 
are reported mainly contributed by the soy isoflavones (131-132). Therefore it can be 
expected that variations in isoflavone quantities will affect the effectiveness of 
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soybeans, or products synthesized from soybeans. The results in the project help to 
verify the quantities of isoflavones in each soybean line, assisting the selection of a 
line for production of soy products when necessary. 
The HPLC results indicate that the quantities of isoflavones in the given soybean 
lines have a large variation (Table 4.2.1-Table 4.2.3), while this can be multifactorial. 
As discussed, the isoflavones are produced as secondary metabolites in the soybean 
for various functions (90-93). The production of these compounds can be influenced 
by the external environment (112-115), for example the irrigation in this project. It is 
also speculated that the genomic composition has also involved in the variation 
(116-117)，most probably will be a combinational effect of genotype and environment. 
5.3. Comparison of selected isoflavones among 19 soybean samples 
5.3.1. Comparison of sum of selected isoflavones between parent and soybeans 
harvested from irrigated land 
It is important to identify whether the derivatives are more productive in terms of 
selected isoflavones than the parent soybean. As the parent was grown in the irrigated 
land, the sums of selected isoflavones in soybeans harvested from irrigated land are 
used for comparison with one-way A N O V A followed by Tukey test. 
The results indicate that the parent soybean has a content of selected isoflavones 
ranked at the position among the 9 tested soybean samples (Fig.4.2.1), and only 1 
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soybean sample can produce significantly more selected isoflavones than the parent. 
The remaining 7 lines give around 40% less selected isoflavones than the parent. 
From these, it can be concluded that generally the produced lines are worse than 
the parent in terms of isoflavone production. Besides, more importantly, as all the 
soybeans involved in the comparison are cultivated under the similar growing 
condition which is irrigated land, variation in sums of selected isoflavones can still be 
observed. The results imply the variations in isoflavone contents can be due to the 
difference in soybean genotypes. The result agrees with the previous report that the 
genomic factors will play a role in isoflavone production (113, 117-118). Diflferent 
soybean lines will give significantly difTererU amount of isoflavones. 
5.3.2. Comparison of sum of selected isoflavones between soybeans harvested 
from non-irrigated land 
The degree of variation in isoflavone contents among the soybeans from 
non-irrigated land is larger than that in beans from irrigation land (Fig.4.4.1). The 9 
soybean samples compared can roughly be divided into 3 groups. 4 soybeans produce 
relatively less, 1 gives moderate amount and the remaining 4 contains relatively more 
selected isoflavones. The variation is obvious as 6 out of 9 tested soybeans show the 
significant difference in their isoflavone contents. 
5.3.3. Comparison of selected isoflavones between soybeans harvested from 
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irrigated land 
Concerning the parent soybean D19 (U, irrigated), it produces moderate content 
of daidzin, daidzein and genistein (Fig.4.5.1). 2 soybeans produce significantly more 
and 4 give less daidzin than D19. In daidzein and genistein, compare to D19, 1-2 
soybeans can have a higher content of isoflavone, while 6 soybeans produce less. In 
glycitin and genistin, D19 has relatively high content. Except having similar content 
as 3 soybeans, all the others produce significantly less than D19. 
In general, D19 produced relative high content of selected isoflavones when 
compared to the soybeans harvested from irrigated land. 
Concerning the tested soybean lines, fluctuations in contents can be observed in 
all 5 isoflavones (Fig.4.4.1). The fluctuation patterns in daidzin, glycitin and genistin 
are similar. Among the 9 compared irrigated land soybeans, 3 to 4 produced 
significantly less isoflavones. The other 5 to 6 soybeans produced more and their 
contents are comparable. 
The patterns of fluctuation in daidzein and genistein are different from the other 
3 isoflavones, but they are similar to each other. 6 soybeans produce significantly less 
amount of isoflavone, with 3 having significantly more. 
The similar pattern of variation may imply that the production of those 
isoflavones can be influenced by some common factors. 
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5.3.4. Comparison of selected isoflavones between soybeans harvested from 
non-irrigated land 
Fluctuation in contents can be observed in all 5 isoflavones (Fig.4.6.1). The 
fluctuation patterns in daidzin and genistin are quite similar. Among the 9 compared 
non-irrigated land soybeans, 4 produce significantly less isoflavone and they have 
similar amounts. 3 soybeans produce more, and the remaining 2 have relatively high 
content of isoflavone. 
The variation patterns in daidzein and genistein are also similar to each other. 3 
soybeans produce relatively less isoflavone at similar contents, and the other 4 have 
more. The remaining 2 produce significantly higher content of isoflavone. 
In glycitin, 4 out of 9 soybeans contain significantly different contents, and the 
remaining 5 have comparable amount of glycitin. 
As the soybeans in each of the above comparison were cultivated under similar 
environment and significant variations could be observed, it implies the variations in 
isoflavone contents could be due to the difference in soybean genotypes. The result 
agrees with the previous report that the genomic factors will play a role in isoflavone 
production (113, 117-118). 
5.3.5. Comparison of sum of selected isoflavones between soybeans harvested 
from irrigated land and drought land 
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In the 9 varieties, 7 out of 9 show the significant difference in isoflavone content 
when growing in different conditions (Fig.4.7.1). For the effect of treatment, it could 
be concluded that, irrigation has a significant effect on production of 5 selected 
isoflavones. Generally, soybeans grew in the irrigated land can produce 1.5 folds 
more isoflavones than the drought land counterpart. The result agrees with the 
previous report that irrigation will play a role in isoflavone production, which can 
stimulate the isoflavone production (115-116). 
The above results indicate that, in general, the production of the selected 
isoflavones in soybeans can be influenced by both genotype and external environment, 
while the detail mechanisms for the phenomenon remain to be revealed. 
5.4. Comparison of anti-proliferation activities of 19 soybean samples 
5.4.1, Comparison of anti-proliferation activities of 19 soybean samples among 5 
cancer cell lines 
The anti-proliferation activities of 19 soybean samples were tested on 5 human 
cancer cell lines including the lung cancer (A549), the leukemia (K-562), the breast 
cancer (MCF7), the osteosarcoma (MG-63) and the prostate cancer (PC-3) cell line. 
These 5 cancers are initiated from different origins and classified into different 
categories. By performing tests on these cell lines, the general anti-proliferation 
efficiencies of soybean extracts on various groups of cancer can be estimated. 
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It could be observed that all the tested soybean extracts possess certain degree of 
anti-proliferation abilities, as all of them can 100% inhibit the proliferation of the 5 
cancer cell lines when the concentration is high enough (Appendix 8.2.2). 
In table 4.8.2.1 and 4.8.2.2, it can be observed that the anti-proliferation 
potencies of the produced soybean lines are generally higher than the parent except 
D02 (H8053, irrigated), DOS (H8301, non-irrigated) and D17 (HK8596, non-irrigated). 
However, it should be noticed that the HPLC analysis revealed higher content of 
selected isoflavones in D19 (U, irrigated) than the produced lines. The results imply 
that there may be some unknown components other than the selected isoflavones 
present only in the lines. These unknown components may be responsible for the 
significantly lower anti-proliferation activities of the lines. 
However, even though all of the extracts are effective, there is a variation in 
effectiveness. This variation excesses both within a single, and also across 5 cell lines 
(Table 4.8.2.1). Concerning a single cell lines, for example the A549, the lowest ED50 
is 13.64 mg/ml by DOl (H8053, non-irrigated) and the highest is 48.65 mg/ml by D19. 
The two ED50S difference by 3.57 folds and similar phenomenon can also be observed 
in other cell lines. It implies that the presence of, or contents of some anti-cancer 
components in the extracts may vary among the 19 soybean lines. 
Moreover, it is also observed that the ED50S fluctuates across the 5 cell lines 
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(Table 4.8.2.1). A549 cell line got the highest average ED50 which is 23.82 mg/ml, 
and MG-63 cell line got the lowest which is 7.45 mg/ml. The 3.2 folds difference 
indicates the susceptibility of various cell lines to soybean extracts can be different. 
One possibility is due to the difference in natures of the cell lines. A particular 
molecule targeted by the anticancer component in soybean extracts may be highly 
expressed in one cell line but not in other. Therefore it can be expected that, with 
more targets to act on, the anti-cancer component in soybean extracts can exert the 
anti-proliferation activities in a more effective way and leading to low ED50. 
5.4.2. Comparison of anti-proliferation potencies of 19 soybean samples 
The rank of ED50 of each soybean on 5 cell lines are summed up, and the 
soybean with the smallest summed rank is considered as the most potent soybean. By 
these criteria, D03 (H8110, non-irrigated) is regarded as the most potent soybean line 
(Table 4.8.2.2). It should also be noticed that, D04 (H8110, irrigated), the irrigated 
counterpart of D03, is having very similar summed rank as D03. Therefore it is nearly 
as potent as D03. As D03 and D04 belong to the same line, it implies this line is 
generally potent to the cancers, regardless the growing condition. It will be important 
for fully utilize of agricultural land resource, as culturing of this potent soybean line 
can be achieved even in drought land. 
5.4.3. Comparison of anti-proliferation activities of 19 soybean samples and 
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corresponding sum of selected isoflavones 
The results indicate that the sum of selected isoflavones fluctuate as the summed 
rank of ED50S (summed rank) increase, therefore no relationship can be determined 
from the analysis (Fig.4.9.1). 
Although an inversely proportion can be observed when certain soybean samples 
are considered, the relationship cannot be established when more soybeans are 
considered. 
The isoflavone content of D03 is not the highest, while it has the lowest summed 
rank and considered as the most potent. Furthermore in DOl (H8053, non-irrigated) 
and D09 (HK8597, non-irrigated), they have significantly lower contents of sum of 
selected isoflavones, yet their anti-cancer activities are ranked as the and the 
respectively. Similar phenomenon can also be observed in some other soybean 
samples. These observations imply that, although the 5 selected isoflavones have 
certain level of anti-proliferation effects on the cell lines, they may not be the major 
anti-proliferation components in the soybeans. It is speculated there are some other 
undetected isoflavones or chemicals responsible for the anti-proliferation activities. 
They are so potent that masking the effects of isoflavones leading to the observed 
results. However, it is just a speculation and more detail study is needed to verify the 
reason behind the observation. 
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5.4.4. Comparison of EDsos from soybeans harvested from irrigated land and 
non-irrigated land 
Comparing with the parent soybean, 3 soybeans show an average rank of ED50 
(average rank) similar to the parent (Fig.4.10.1). It indicates that the produced lines 
are generally more potent than the parent. One possibility is that there are other 
chemicals could only be produced in varieties but not parent. The chemicals may be 
very potent that leads to the low average rank in lines. 
Comparing the average rank in produced soybean lines, variation can be 
observed. Concerning the soybeans from irrigated land, the average rank differs 
significantly. It is speculated that, with different genotypes, chemicals produced in 
soybeans may vary in types or quantities. It is possible that certain potent 
anti-proliferative compound is present in some soybean lines but not in others, or 
certain lines can produce larger amount of such potent components, leading to 
variations in components of extracts and the observation. 
Comparing the average ranks of beans belong to the same line, only 4 pairs of 
lines have significant difference, and 3 of them have lower ranks in beans from 
irrigated land. The remaining 1 is the opposite. As irrigation only show the effect on 
around half of the varieties investigated, it is difficult to conclude whether irrigation 
really have an effect on the anti-proliferation activities. 
5.4.5. Correlation Of Isoflavones And Anti-Proliferation Potencies 
It has been suggested that the anti-proliferation abilities of soybean extracts are 
due to the presence of soy isoflavones (131-136). Therefore in the project, the 5 major 
soy isoflavones, daidzin, glycitin, genistin, daidzein and genistein were selected for 
analysis. Their quantities were measured by HPLC and statistical analysis was 
performed to determine the possible correlation between these isoflavones and the 
anti-proliferation effect of soybeans. 
The statistical analysis indicates that, the anti-proliferation effect of soybean 
extracts on the breast cancer cell line MCF7 is significantly correlated to the presence 
of daidzin and genistin in the soybeans. The concentration of these two isoflavones is 
inversely proportional to the ED50 on MCF7 cell line, thus the higher concentration 
will give a lower ED50. The result implies that daidzin and genistin may be one of the 
major effective anti-proliferation components in soybean inhibiting the proliferation 
of the breast cancer cell line. Continuous investigation on daidzin and genistin may 
help to determine the effectiveness of soybean or soy products on treatment of breast 
cancer. The working mechanism of these isoflavones on MCF7 cell line may also 
provide some insights on the pathology of breast cancer. 
Comparing with the previously studies, the potencies of selected isoflavones in 
the project is lowered than expected. It has been reported that the IC50 of genistein on 
MCF7 cell line is about 10 fig/ml (134), while in the project, for example in D03 
92 
(H8110, non-irrigated), the ED.so is 13.47 mg/ml. and the concentration of genistein in 
ED50 is 27.4 ^ g/ml. The value is higher than the reported IC50. This can be due to the 
fact that, according to the extraction protocol, the soybean extracts tested in the 
project is a mixture of chemicals dissolved in 70% ethanol. There may be some 
chemicals which act as the inhibitor of genistein. reducing its anti-proliferation effect. 
It is also possible that there are some other unrevealed potent anti-proliferation 
compounds inside the soybean. They act as the major anti-proliferation components in 
the soybean extracts and masked the effect of genistein. 
Besides the above, no other correlations can be determined from the isoflavones 
and the anti-proliferation abilities. This can imply that, isoflavones may possibly be 
one of the effective anti-proliferative components in soybeans, but not the major one, 
at least for the selected isoflavones on the tested cancer cell lines. There may be some 
other chemicals with similar polarity as the isoflavones and extracted by the protocol 
used. These components present in the soy extracts and are responsible for the 
anti-proliferative effects. The identities remain to be elucidated. 
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6. Conclusion 
The project indicated the significant variation in isoflavone contents and the 
potency of anti-proliferation of cancer cells in various soybean lines. The parent 
soybean D19 (U) is found to produce more of the 5 selected isoflavones than the 
varieties. However the varieties are more potent in anti-proliferation activities. 
Statistical analysis has proven the effect of genotype on isoflavone production and 
anti-proliferation abilities. The irrigation was also found to be significant on 
production of the 5 selected isoflavones, while its effect on the anti-proliferation 
activities is inconclusive. The anti-proliferation effect of soybeans on MCF7 cell line 
(breast cancer) is found to be correlated to the amount of daidzin and genistin in the 
soy extracts, while no correlations was able to be determined from other cell lines. 
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Fig.8.1.1 The HPLC standard curve of daidzin 100 |ig/ml, 200 i^g/ml and 400 
|ag/ml of daidzin was analyzed in triplicate by HPLC. The average peak areas were 
taken to plot against the concentrations giving the standard curve with a R^ of 1.0. 
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8. Appendix 
8.1. HPLC analysis of the 5 selected isoflavones standard and 2-phenyIchromone 
8.1.1. HPLC standard curves for 5 selected isoflavones and 2-phenylchromone 
A serial concentration of the 5 selected isoflavones and 2-phenylchromone were 
analyzed by HPLC. The average peak areas were plotted against the concentrations to 
produce standard curves for calibration. 
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Fig.8.1.2 The HPLC Standard Curve of Glycitin 25 ^g/ml, 50 i^g/ml, 100 ug/ml 
and 200 jig/ml of glycitin was analyzed in triplicate by HPLC. The average peak areas 
were taken to plot against the concentrations giving the standard curve with a R^ of 
HPLC Standard Curves of Genistin 
50000-
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Fig.8.1.3 The HPLC Standard Curve of Genistin 200 ug/ml, 400 jig/ml, 800 fig/ml 
of genistin was analyzed in triplicate by HPLC. The average peak areas were taken to 
plot against the concentrations giving the standard curve with a R^ of 0.936. 
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Fig.8.1.4 The HPLC Standard Curve of Daidzein 10 i^g/ml, 50 ^g/ml and 100 
|xg/ml of daidzein was analyzed in triplicate by HPLC. The average peak areas were 
taken to plot against the concentrations giving the standard curve with a R^ of 0.998. 
Concentration of Genistein (ug/ml) 
Fig.8.1.5 The HPLC Standard Curve of Genistein 10 ^ ig/ml, 40 ^g/ml and 100 
|Ag/ml of genistein was analyzed in triplicate by HPLC. The average peak areas were 
taken to plot against the concentrations giving the standard curve with a R^ of 0.999. 
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Fig.8.1.6 The HPLC Standard Curve of 2-phenylchromone 25 |^ g/ml, 50 \ig/m\ 
and 100 |j,g/ml of 2-phenylchromone was analyzed in triplicate by HPLC. The average 
peak areas were taken to plot against the concentrations giving the standard curve 
with a r2 of 1.0. 
8.1.2. Details of HPLC analysis of the 19 soybean lines 
The data from HPLC analysis was adjusted with the 2-phenylchromone for 
differences in extraction efficiencies. After the adjustment, the peak areas can be used 
for determination of quantities of isoflavones per gram of soybean. 
Table 8.1.2.1 The normalized peak areas of selected isoflavones in soybean lines 
Soybean Line 
Peak Area Normalized with Internal Control 
Daidzin Glycitin Genistin Daidzein || Genistein 
DOl 
5312.36 7784.64 20738.84 608.98 781.43 
5224.29 7721.35 20442.17 599.51 745.37 
5266.72 7364.60 20429.37 593.49 738.86 
D02 
22993.56 7981.25 59079.96 1755.76 2145.48 
22921.46 7894.79 58656.72 1753.51 2155.94 
23165.98 8031.06 58573.75 1835.47 2228.86 
D03 
26651.86 11561.86 76991.81 2071.49 2214.95 
26425.11 12165.52 77152.88 1934.81 2078.31 
26777.05 11391.99 75366.11 2031.87 2144.93 
D04 
38077.09 9861.27 91873.31 2121.98 2156.09 
39568.22 10335.33 92172.73 2234.27 2135.05 
39917.92 10608.98 93706.88 2483.19 2265.11 
D05 
14204.83 8954.39 46067.10 1789.80 1535.78 
15411.85 9752.23 49287.02 1882.70 1567.00 
15243.63 9559.34 48669.95 1863.41 1539.38 
D06 
35921.00 13078.51 84718.78 2512.04 2021.71 
34188.94 12547.47 80151.90 2596.70 2199.56 
34067.13 12527.76 79551.07 2583.02 2217.75 
D07 
21400.57 8148.72 68468.19 1768.13 1706.59 
21449.97 8335.20 68790.69 1971.28 1781.96 
21901.83 8503.46 68874.17 2018.39 1812.57 
D08 
51783.89 12663.16 95104.79 4929.05 3771.41 
52252.98 12332.81 93468.04 4492.46 3536.16 
44302.77 10919.39 79352.49 4576.25 3553.03 
119 
5607.71 6225.54 24343.87 944.73 441.47 
D09 5404.74 5675.41 23673.02 542.44 416.92 
5463.83 6127.27 23646.92 546.17 331.17 
17023.96 9208.60 55648.30 2102.48 1976.20 
DIO 16936.36 9096.13 54850.31 2030.53 1868.71 
16448.58 9025.55 55389.94 2068.75 1854.45 
19166.39 9560.90 59946.25 2807.18 2535.15 
Dll 21140.13 10559.73 64585.85 3051.62 2731.99 
19551.12 9657.67 60127.20 2884.00 2544.32 
17770.39 9612.68 60531.86 2145.96 2045.90 
D12 17868.81 9826.79 60647.42 2729.73 2063.94 
17206.67 9428.02 58381.83 2119.80 1 1853.41 
29990.47 12711.39 76657.47 6164.77 2996.72 
D13 32242.08 13649.03 81813.16 6156.64 3174.96 
32711.97 13795.74 81408.63 6143.67 3325.30 
29800.39 10122.11 69508.98 4842.87 3006.93 
D14 33159.33 11268.72 78458.54 5195.34 3102.06 
30632.70 10399.34 70391.23 4785.93 2989.34 
6494.78 7257.20 30405.33 2185.40 1292.66 
D15 6512.92 7384.01 30612.51 2226.45 1298.39 
7439.78 8390.46 33537.69 1149.09 1124.94 
18819.34 11504.28 80240.37 5269.48 3492.04 
D16 19021.59 11642.94 80854.40 3886.08 3500.23 
18771.08 11547.67 80311.31 5263.66 2506.58 
7121.32 3601.40 25552.36 407.35 623.56 
D17 6966.04 3597.92 25435.03 427.38 679.03 
7081.35 3602.88 25550.92 418.87 726.80 
26057.14 8645.33 76770.65 2572.85 1953.49 
D18 26176.54 8630.11 76925.07 2693.01 1724.80 
26641.75 8808.56 77025.09 2504.56 1640.29 
30443.01 12209.19 90411.64 3908.56 2954.40 
D19 31129.58 12377.56 91746.62 3857.14 2866.27 
30621.80 12175.11 89817.38 3906.53 2979.09 
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Table 8.1.2.2 The quantities of selected isoflavones in soybean lines 
Soybean 
Line 
Quantities of Isoflavones per 1 gram of soybean (ja.g/g) 
Daidzin Glycitin Genistin Daidzein Genistein 
Sum of 5 
Isoflavones 
Average of 
Sum of 5 
Isoflavones 
289.19 173.61 309.75 5.60 6.94 785.09 
DOl 284.41 172.19 298.26 5.49 6.58 766.94 770.88 
286.71 164.19 297.77 5.43 6.52 760.61 
1249.42 178.02 1794.11 18.38 20.37 3260.30 
D02 1245.51 176.08 1777.73 18.35 20.47 3238.14 3250.44 
1258.79 179.14 1774.52 19.27 21.19 3252.89 
1448.10 258.33 2487.57 21.90 21.05 4236.94 
D03 1435.78 271.87 2493.80 20.37 19.71 4241.53 4218.11 
1454.90 254.52 2424.63 21.45 20.36 4175.86 
2068.58 220.19 3063.70 22.46 20.47 5395.39 
D04 2149.56 230.82 3075.29 23.71 20.26 5499.64 5494.42 
2168.55 236.96 3134.68 26.48 21.54 5588.22 
772.12 199.85 1290.33 18.76 14.36 2295.42 
DOS 837.67 217.74 1414.98 19.79 14.67 2504.86 2422.43 
828.54 213.42 1391.09 19.58 14.40 2467.02 
1951.48 292.35 2786.71 26.81 19.15 5076.50 
D06 1857.42 280.44 2609.91 27.75 20.90 4796.41 4879.68 
1850.80 280.00 2586.65 27.60 21.08 4766.12 
1162.91 181.78 2157.58 18.52 16.04 3536.82 
D07 1165.59 185.96 2170.06 20.78 16.79 3559.18 3562.52 
1190.13 189.73 2173.29 21.30 17.09 3591.55 
2812.97 283.03 3188.80 53.74 36.38 6374.92 
D08 2838.44 275.62 3125.44 48.87 34.06 6322.43 6003.65 
2406.68 243.92 2578.96 49.81 34.23 5313.59 
305.23 138.64 449.32 9.34 3.59 906.12 
D09 294.21 126.30 423.35 4.86 3.35 852.06 873.92 
297.42 136.44 422.34 4.90 2.50 863.59 
S 7 
925.22 205.55 1661.26 22.24 18.70 2832.97 
DIO 920.47 203.03 1630.36 21.44 17.64 2792.94 2803.99 
893.98 201.44 1651.26 21.87 17.50 2786.04 
1041.58 213.45 1827.65 30.09 24.20 3136.98 
Dll 1148.77 235.85 2007.27 32.82 26.14 3450.85 3251.94 
1062.47 215.62 1834.66 30.95 24.29 3167.99 
965.76 214.61 1850.32 22.73 19.39 3072.81 
D12 971.11 219.41 1854.80 29.23 19.56 3094.11 3039.85 
935.15 210.47 1767.09 22.43 17.49 2952.63 
1629.41 284.11 2474.62 67.51 28.75 4484.40 
D13 1751.69 305.15 2674.22 67.41 30.50 4828.98 4718.95 
1777.21 308.44 2658.56 67.27 31.98 4843.46 
1619.09 226.04 2197.87 52.78 28.85 4124.62 
D14 1801.50 251.76 2544.35 56.70 29.79 4684.10 4339.37 
1664.29 232.26 2232.03 52.14 28.68 4209.39 
353.41 161.78 683.98 23.17 11.97 1234.31 
D15 354.39 164.62 692.01 23.62 12.03 1246.67 1300.03 
404.73 187.20 805.25 11.62 10.32 1419.12 
1022.73 257.04 2613.33 57.53 33.63 3984.26 
D16 1033.71 260.15 2637.10 42.12 33.71 4006.79 3988.88 
1020.11 258.01 2616.08 57.46 23.92 3975.59 
387.43 79.78 496.10 3.35 5.38 972.05 
D17 379.00 79.71 491.56 3.58 5.93 959.77 967.61 
385.26 79.82 496.05 3.48 6.40 971.01 
1415.80 192.92 2479.00 27.48 18.48 4133.68 
D18 1422.28 192.57 2484.98 28.82 16.22 4144.88 4151.22 
1447.55 196.58 2488.85 26.72 15.39 4175.09 
1653.99 272.85 3007.11 42.37 28.33 5004.64 
D19 1691.27 276.63 3058.79 41.79 27.46 5095.95 5030.47 
1663.70 272.09 2984.10 42.34 28.58 4990.80 
S 8 
8.2. Anti-proliferation abilities of various soybean lines 
8.2.1. Anti-proliferation test of ethanol and 2-phenylchromone 
As the ethanol and 2-phenylchromone is cytotoxic, it is important to be sure that 
the concentration of ethanol and 2-phenylchromone in anti-proliferation assays for 
soybean extracts has no effect on the growth of cell lines. The dose-response curves of 
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Fig.8.2.1.1 The effect of ethanol on proliferation of 5 cancer cell lines a.A549 cells, 
b. K-562 cells, c. MCF7 cells, d. MG-63 cells, e. PC-3 cells were subjected to ethanol 
induction from concentration of 25% to 0.0244% (Percentage / volume) in two-fold 
serial dilution manner for 4 cell cycles with the anti-proliferation assay protocol 
mentioned previously. M T T assay was performed for determination of dose-response 
relationship. The data in the figure are mean 士 S.E.M, n=3. 
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Fig.8.2.1.2 The effect of 2-phenylchromone on proliferation of 5 cancer cell lines 
a.A549 cells, b. K-562 cells, c. MCF7 cells, d. MG-63 cells, e. PC-3 cells were 
subjected to 2-phenylchromone induction from concentration of 375 |ig of 
2-phenylchromone/ml to 0.37 |ig/ml in two-fold serial dilution manner for 4 cell 
cycles with the anti-proliferation assay protocol mentioned previously. M T T assay 
was performed for determination of dose-response relationship. The data in the figure 
mean 士 S.E.M，n=3. 
S 1 5 
8.2.2. Anti-Prol i feration Test Of 19 Soybean Lines O n 5 H u m a n Cell Lines 
The anti-proliferation effect of soybean extracts was tested on 5 human cancer 
cell lines by M T T assay. The data was used for construction of dose-response curve 
and for determination of IC50S. 
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Fig.8.2.2.1 The anti-proliferation effect of 19 soybean samples on A549 cell line 
The lung cancer cell line A549 was subjected to the induction of extract from a-s. 
soybean D01-D19 at concentration of 87.5 mg/ml to 85.4 |ig/ml (weight of raw 
soybean materials per one milliliter) in two-fold serial dilution manner for 4 cell 
cycles. MTT assay was performed for determination of dose-response relationship. 
The data in the figure are mean 士 S.E.M, n=3. 
S 2 6 
Anti-Proliferation Effect of 
D01 on MG-63 Cell line 
I 
0.1 1 10 100 
Soybean Extract D01 (mg/ml) 
1000 
Anti-Proliferation Effect of 
D02 on K-562 Cell line 
0.1 1 10 100 
Soybean Extract D02 (mg/ml) 
1000 













( 0 / 0 )
 C O L S C -
 ^ O
 E S E N I E O J ① D 
a 
( 0 / 0 )
 C O L S C -
 I O
 9 6 E H J 9 3 」 ① D 
b 
Anti-Proliferation Effect of 
D03 on K-562 Cell line 
0.1 1 10 100 
Soybean Extract D03 (mg/ml) 
1000 
Anti-Proliferation Effect of 
D04 on K-562 Cell line 
0.1 1 10 100 
Soybean Extract D04 (mg/ml) 
1000 













( 0 / 0 )
 C O L Z C - 如 O
 A B E ^ J E O J E D 
( 0 / 0 )
 C O L Z C -
 I O
 E B E I U E O J E D 
d 
Anti-Proliferation Effect of 
DOS on K-562 Cell line 
0.1 1 10 100 
Soybean Extract DOS (mg/ml) 
1000 
Anti-Proliferation Effect of 
D06 on K-562 Cell line 
A 
• T • � 
0.1 1 10 
Soybeab Extract D06 (mg/ml) 
100 1000 







( 0 / 0 )
 C O L S C -
 I O









 u o j s c l l L I U I




Anti-Proliferation Effect of 
D07 on K-562 Cell line 
0.1 1 10 100 1000 




Anti-Proliferation Effect of 
DOS on K-562 Cell line 
0.1 1 10 100 
Soybean Extract DOS (mg/ml) 
1000 
S 3 0 
( 0 / 0 )
 u o ! 和 ！ c l l l ^ u l
 ) o
 ① O J e d 
g 
(％)
 u o i l q u i
 p
 ① B e i o j e d
 . 
h 
Anti-Proliferation Effect of 
D09 on PC-3 Cell line 
A A 
0.1 1 10 100 
Soybean Extract D09 (mg/ml) 
1000 
Anti-Proliferation Effect of 
D10on K-562 Cell line 
0.1 1 10 100 
Soybean Extract D18 (mg/ml) 
1000 















 3 6 E L O J E D 
( 0 / 0 )
 U0!}!Q!L{U|
 ) O
 ① B E H ^ ① 
Anti-Proliferation Effect of 
D11 on K-562 Cell line 
Anti-Proliferation Effect of 
D12on K-562 Cell line 
0.1 1 10 100 1000 
Soybean Extract D12 (mg/ml) 
k . 
0.01 0.1 1 10 100 
Soybean Extract D11 (mg/ml) 
1000 







( 0 / 0 )
 C O L S C -
 I O













( 0 / 0 )
 u o ! } ! q ! q u |
 ) o
 ① B e n i e o j ① d 
Anti-Proliferation Effect of 
D13 on K-562 Cell line 
0.1 1 10 100 
Soybean Extract D13 (mg/ml) 
1000 
Anti-Proliferation Effect of 
D14on K-562 Cell line 
0.1 1 10 100 
Soybean Extract D14 (mg/ml) 
1000 







( 0 / 0 )
 c o l s c ^








( 0 / 0 )
 UO!}!Q!L|U|
 如O
 ① B E N J E O I ① D 
n. 
Anti-Proliferation Effect of 
D15on K-562 Cell line 
U 
0.1 1 10 100 
Soybean Extract D15 (mg/ml) 
1000 
Anti-Proliferation Effect of 
D16on K-562 Cell line 
0.1 1 10 100 
Soybean Extract D16 (mg/ml) 
1000 













( 0 / 0 )
 u o ! 二 q ! q u |
 ^ o
 ① B e j u ① O J ① d 
0 
( 0 / 0 )
 如O
 ① 6 E I U E 0 J 9 D 
P 
Anti-Proliferation Effect of 
D09 on PC-3 Cell line 
0.1 1 10 100 
Soybean Extract D17 (mg/ml) 
1000 
Anti-Proliferation Effect of 
D18on K-562 Cell line 
0.1 1 10 100 
Soybean Extract D18 (mg/ml) 
1000 








 U 芸！ Q ! Q U |
 ^ O



















Anti-Proliferation Effect of 
D19on K-562 Cell line 
01 0.1 1 10 100 1000 
Soybean Extract D19 (mg/ml) 
Fig.8.2.2.2 The anti-proliferation effect of 19 soybean samples on K-562 cell line 
The leukemia cell line K-562 was subjected to the induction of extract from a-s. 
soybean D01-D19 at concentration of 87.5 mg/ml to 85.4 昭 /ml (weight of raw 
soybean materials per one milliliter) in two-fold serial dilution manner for 4 cell 
cycles. MTT assay was performed for determination of dose-response relationship. 
The data in the figure are mean 士 S.E.M, n=3. 
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Fig.8.2.2.3 The anti-proliferation effect of 19 soybean samples on MCF7 cell line 
The breast cancer cell line MCF7 was subjected to the induction of extract from a-s. 
soybean D01-D19 at concentration of 87.5 mg/ml to 85.4 |ig/ml (weight of raw 
soybean materials per one milliliter) in two-fold serial dilution manner for 4 cell 
cycles. MTT assay was performed for determination of dose-response relationship. 
The data in the figure are mean 士 S.E.M，n=3. 
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Fig.8.2.2.4 The anti-proliferation effect of 19 soybean samples on MG-63 cell line 
The osteosarcoma cell line MG-63 was subjected to the induction of extract from a-s. 
soybean D01-D19 at concentration of 87.5 mg/ml to 85.4 |ig/ml (weight of raw 
soybean materials per one milliliter) in two-fold serial dilution manner for 4 cell 
cycles. MTT assay was performed for determination of dose-response relationship. 
The data in the figure are mean 士 S.E.M, n=3. 
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Fig.8.2.2.5 The anti-proliferation effect of 19 soybean samples on PC-3 cell line 
The prostate cancer cell line PC-3 was subjected to the induction of extract from a-s. 
soybean D01-D19 at concentration of 87.5 mg/ml to 85.4 ^ig/ml (weight of raw 
soybean materials per one milliliter) in two-fold serial dilution manner for 4 cell 
cycles. MTT assay was performed for determination of dose-response relationship. 
The data in the figure are mean 土 S.E.M, n=3. 
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8.3. Effects of isoflavones on anti-proliferation activities 
Effects of isoflavones on the anti-proliferation activities on 5 cancer cell lines 
were analyzed with correlation analysis and the results are presented as below. 
Correlation between Sum of Selected Isoflavones 











( I U I / 6 U J )
 S 0 S 3
 • 
b 




( I E / B E )
 w o s m 
i * p = 0.0081 
R2= 0.3832 
i £ 
Correlation between Sum of Selected Isoflavones 
and EDSOs on MCF7 cell line 
0-
0 2000 4000 6000 8000 
Sum of Selected Isoflavones (ug/g) 
S 6 8 
0. 0 2000 4000 6000 8000 
Sum of Selected Isoflavones (ug/g) 
Correlation between Sum of Selected Isoflavones 





( I E / B E )
 w o s m 
H H 霣 
i I 
0 5 1 
( I E / B E )
 S 0 9 A 3 
Correlation between Sum of Selected Isoflavones 












0 2000 4000 6000 8000 
Sum of Selected Isoflavones (ug/g) 
Fig.8.3.1 The correlation between sum of selected isoflavones and EDsoS on 5 
cancer cell lines The sums of selected isoflavones of soybean lines were analyzed 
against the ED50S on a. A549 cell line, b. K-562 cell line, c. MCF7 cell line, d. MG-63 
cell line, e. PC-3 cell line for correlation. A correlation can be determined between the 
concentration of sum of selected isoflavones and anti-proliferation activities on MCF7 
cell line, with p=0.0081. The data in the figure are mean 土 S.E.M, n=3. 
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Fig.8.3.2 The correlation between concentration of daidzin and EDsoS on 5 cancer 
cell lines The concentrations of daidzin in soybean lines was analyzed against the 
ED50S on a. A549 cell line, b. K-562 cell line, c. MCF7 cell line, d. MG-63 cell line, e. 
PC-3 cell line for correlation. A correlation can be determined between the 
concentration of daidzin and anti-proliferation activities on MCF7 cell line, with 
p=0.016. The data in the figure are mean 士 S.E.M, n=3. 
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Fig.8.3.3 The correlation between concentration of glycitin and EDsoS on 5 cancer 
cell lines The concentrations of glycitin in soybean lines was analyzed against the 
ED50S on a. A549 cell line, b. K-562 cell line, c. MCF7 cell line, d. MG-63 cell line, e. 
PC-3 cell line for correlation. The data in the figure are mean 士 S.E.M, n=3. 
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Fig.8.3.4 The correlation between concentration of genistin and EDsoS on 5 
cancer cell lines The concentrations of genistin in soybean lines was analyzed against 
the EDsos on a. A549 cell line, b. K-562 cell line, c. MCF7 cell line, d. MG-63 cell 
line, e. PC-3 cell line for correlation. A correlation can be determined between the 
concentration of genistin and anti-proliferation activities on MCF7 cell line, with 
p=0.0059. The data in the figure are mean 士 S.E.M, n=3. 
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Fig.8.3.5 The correlation between concentration of daidzein and ED50S on 5 
cancer cell lines The concentrations of daidzein in soybean lines was analyzed 
against the ED50S on a. A549 cell line, b. K-562 cell line, c. MCF7 cell line, d. MG-63 
cell line, e. PC-3 cell line for correlation. The data in the figure are mean 士 S.E.M’ 
n=3. 
Correlation between Daidzein 




i i • • 
. 1 1 
0505 2 11 
( _ E / 6 E )
 S 0 9 A 3 
0 10 20 30 
Concentration of Genistein (ug/g) 
25-
Correlation between Genistein 
and EDSOs on K-562 cell line 
Correlation between Genistein 
and EDSOs on A549 cell line 
vr 
0 10 20 30 
Concentration of Genistein (ug/g) 










( I E / B E )












( IUJ /6UJ )
 w o s m
 • 
a 
Correlation between Genistein 
and EDSOs on MCF7 cell line 
i 
i 
10 20 30 40 
Concentration of Genistein (ug/g) 
Correlation between Genistein 
and EDSOs on MG-63 cell line 
d. 
0. 
0 10 20 30 
Concentration of Genistein (ug/g) 







 E / 6 E )





0 5 1 
( I E / B E )
 W O S M 
e, 
0' 
0 10 20 30 40 
Concentration of Genistein (ug/g) 
Fig.8.3.6 The correlation between concentration of genistein and EDsoS on 5 
cancer cell lines The concentrations of genistein in soybean lines was analyzed 
against the ED50S on a. A549 cell line, b. K-562 cell line, c. MCF7 cell line, d. MG-63 
cell line, e. PC-3 cell line for correlation. The data in the figure are mean 士 S.E.M, 
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